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Kurzreferat: 
 
Psoriasis and chronic contact dermatitis at the palmoplantar sites cause diagnostic difficul-
ties, especially by isolated involvement. Furthermore, there are many patients with type IV 
sensitisation, showing contemporarily clinical and histological features of both psoriasis and 
contact dermatitis (so-called "eczema in psoriatico"). The purpose of the instant study was to 
compare characteristics of these patients with typical palmoplantar psoriasis and 
palmoplantar allergic contact dermatitis. The hematoxylin-eosin staining was insufficient for 
the distinction of these diseases from one another. By immunochemistry, “eczema in psori-
atico” presented similar alterations in epidermal hyperproliferation to psoriasis (CK17, Ki67, 
filaggrin). “Eczema in psoriatico” showed contemporarily overlapping features with psori-
asis (IL-8, IL-17 and IL-23) and contact dermatitis (CD1a, MHC I, MHC II, epidermal T cell 
subsets). Surprisingly, “eczema in psoriatico” revealed a significantly higher number of der-
mal CD8+ T cells than allergic contact dermatitis and psoriasis. Elevated IgE in serum corre-
lated positively with the number of LCs and negatively with Ki67. Altogether, due to some 
immunohistochemical constellations, „eczema in psoriatico“ (in our opinion a distinct clini-
cal entity of particular importance, with regard to occupational diseases) can be differenti-
ated better from palmoplantar allergic contact dermatitis and palmoplantar psoriasis. Fur-
thermore, our work provides a better understanding of the pathomechanism of psoriasis and 
allergic contact dermatitis in palmoplantar localisation. 
 
Keywords: psoriasis, contact dermatitis, „eczema in psoriatico“, palmoplantar, immuno-
chemistry 
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Introduction 
Diagnostic difficulties of scaling erythema on palms and /or soles 
Psoriasis and chronic eczema at the palmoplantar sites show multiple, overlapping clin-
ical and histological features. Sometimes the differentiation of isolated skin changes on 
palms and soles, is hardly possible. Histologic parameters vary due to anatomic particulari-
ties. Diagnostic difficulties are also combined with heterogeneous aetiology of contact der-
matitis, with possible impact of contact allergy, atopy and irritation on clinical picture and 
therapeutic outcome. Due to mechanical and environmental exposure of hands and feet, pso-
riatic lesions may change their clinical aspect, and may be influenced by irritation and/or 
contact sensitisation. 
A proper diagnosis is crucial for an efficient therapy and is relevant in case of occupational 
causal relationship. 
Clinical data files from our department distinguish a large group of patients with scaling 
erythema on their soles and palms that show clinical and histological features of psoriasis 
and contact dermatitis combined with a high frequency of positive patch tests. This clinical 
and histological constellation is mostly called "eczema in psoriatico".  
Therefore, the purpose of our study was to compare clinical, histological and immunohisto-
logical characteristics in patients with typical palmoplantar psoriasis, as well as typical 
palmoplantar allergic contact dermatitis, and in particular, those showing overlap of both 
diseases. For a more detailed classification and more aetiological homogeneity, the following 
patient groups were excluded from this study: cases with chronic irritant non allergic hand 
and foot manifestation, patients with isolated atopic hand eczema without contact allergy, 
as well as cases with palmoplantar pustular psoriasis. 
Aims of the studies and outline 
The objective of this work is a concept validation of eczematous psoriasis (“eczema in 
psoriatico”) in palmoplantar localisation. This study includes theoretical, clinical and exper-
imental investigations on psoriasis, chronic allergic contact dermatitis and “eczema in pso-
riatico” in palmoplantar localisation with focus on histology and immunohistochemistry. 
Results of epicutaneous patch tests will be discussed in detail. The impact of contact allergy 
on immunohistology is additionally studied.  
Introduction 
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The theoretical background on epidemiology, clinics, histology and pathomechanism of pso-
riasis and contact dermatitis is summarised in Chapter 2. The focus lies on similarities and 
differences, when considering anatomical variations of palms and soles. In conclusion to this, 
the concept of “eczema in psoriatico” is introduced. 
Detailed methodology of allergic tests, as well as of histological and immunohistological 
procedures is provided in Chapter 3.  
Epidemiological data with focus on clinics and allergy tests is summarised in Chapter 4. 
Major attention is given here to the analysis of frequency of type IV sensitisations with dif-
ferent allergens in all examined groups: psoriasis, allergic contact dermatitis and “eczema in 
psoriatico”. 
The subsequent Chapter 5 presents results of the histological investigations. The frequency 
of different histological parameters is evaluated quantitatively and compared among all four 
groups: “eczema in psoriatico”, allergic contact dermatitis, psoriasis and healthy skin by in-
vestigating palmoplantar skin biopsies (H&E stains). 
The most important goal of this thesis is the experimental study by immunohistological 
methods exploring possible, immunological differences in “eczema in psoriatico” in com-
parison to allergic contact dermatitis, psoriasis and healthy skin, by investigating 
palmoplantar skin biopsies with immunochemistry. The results of this study are presented 
in Chapter 6. With the help of different immunostainings, it has successfully been proved, 
that overlapping immunological processes typical for both psoriasis and contact dermatitis 
take place contemporarily in “eczema in psoriatico”. 
The results of this thesis are finally summarised in Chapter 7. Clinical implications of the 
findings, as well as suggestions for further research are discussed in the conclusion. 
This thesis gives a new insight into clinical, histological and immunohistological differenti-
ation between palmoplantar psoriasis and palmoplantar chronic contact dermatitis. We dis-
tinguish a distinct clinical entity ”eczema in psoriatico” with type IV sensitisation and over-
lapping clinical and histological features of both psoriasis and chronic allergic contact der-
matitis. The results allow, to some extent, a better understanding of pathomechanism and 
differentiation between “eczema in psoriatico”, psoriasis and chronic contact dermatitis in 
palmoplantar localisation. This data is also of importance when an occupational background 
is given in the patients’ disease.  
 
 
Theoretical background 
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1. Theoretical background 
This chapter provides basic aspects of epidemiology, morphology, histology and 
pathomechanism of psoriasis and contact dermatitis. This chapter also focuses 
on similarities and differences between both diseases, especially in palmoplantar 
localisation. In conclusion, an introduction of a new concept of “eczema in psori-
atico” will follow. 
1.1 Epidemiology 
1.1.1 Psoriasis 
Psoriasis is a chronic immune-mediated inflammatory skin disease, which is found in 
circa 2% of the world´s population. Its pathogenesis is not completely understood and in-
cludes genetic, environmental and immunological factors. Psoriasis affects men and women 
equally. The highest incidence rate occurs between the 2nd and 3rd decade of life (type I pso-
riasis) and in the 6th decade (type II psoriasis) [1]. Nearly 35-90% of patients with psoriasis 
have a positive family history [2]. A concordance rate in monozygotic twins is significantly 
higher than in dizygotic twins [3,4]. Psoriasis type I, in contrast to psoriasis type II, often has 
a genetic background and is associated with various human leukocyte antigens, like HLA-
Cw6, HLA-B57, HLA-DR7 [5].  
1.1.2 Contact dermatitis 
Contact dermatitis is a heterogeneous, multifactorial disease with variable clinical and 
etiological patterns that affect about 15-20% of the population [6]. Women are affected twice 
as frequently as men (21.8% versus 12%), which is connected with higher exposure to wet 
works at the work place or at home [6]. Contact dermatitis has an early onset with its preva-
lence of 15.2 % in schoolchildren between 12-16 years old [7]. Allergic contact dermatitis 
causes about 20% of all occupational health complaints [8].  
1.2 Morphology 
1.2.1 Psoriasis 
Clinical manifestation of psoriasis are erythrosquamous scaling plaques found most com-
monly at the elbows, knees, scalp and groin as well as multiple pitting and dystrophic 
changes of the nails. The most common clinical variants of psoriasis are psoriasis guttate and 
Theoretical background 
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plaque type. One third of psoriatic patients develop psoriatic arthritis. 
12% of psoriasis patients are affected on their palms and soles. Isolated palmoplantar 
psoriasis occurs in 3-4 % of all psoriasis cases [9]. Palmoplantar lesions are usually bilateral, 
sharply demarcated red plaques with scaling and fissuring and can be palm-sized or distrib-
uted as smaller units over palms and soles (Figure 1). Special entities represent palmoplantar 
pustular psoriasis with erythrosquamous plaques and recurrent sterile pustules. 
Nail changes occurs in 25-50% of all psoriasis patients and allows in some cases differen-
tiating psoriasis in hand- and foot localisation from isolated palmoplantar chronic contact 
dermatitis. Oil spots and onycholysis are specific for psoriasis but rarely occur in eczema. 
Nail pitting can occur in both psoriasis and contact dermatitis.  
The Koebner phenomenon describes the appearance of psoriatic lesions at sites of skin 
trauma. It is believed that palmoplantar psoriasis is continually influenced by Koebnerisa-
tion due to mechanical trauma. 
Psoriasis phenomena reflect histological changes. Upon removal of silvery scales, (equiv-
alent to parakeratosis) the surface appears similar to wax flakes (candle phenomenon- “signe 
de la tache de bougie”). Removal of the latter leads to papillary bleeding (Auspitz´ sign) and 
corresponds to dilated vessels in the papillary dermis and thinning of the suprapapillary 
plates [10]. 
 
1.2.2 Contact dermatitis 
Contact dermatitis is characterised through pruritic papular- and vesicular- eruptions on 
 
Figure 1. Palmoplantar psoriasis with sharply demarcated erythematous plaques with scaling and fissuring. 
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erythematous ground in acute stadium (Figure 2) and lichenification, erythema, scaling, fis-
sures and excoriations in chronic forms.  
Contact dermatitis is often localised palmoplantar. The one-year prevalence of hand eczema 
in the general population accounts for 14% [11]. Foot dermatitis is estimated for 10% of all 
cases with contact dermatitis [12] and has an increased risk for developing of polysensitisa-
tion [13]. 
 
Due to morphology, hand and foot eczema can be divided into vesicular/pompholyx, 
chronic-lichenoid, hyperkeratotic-raghadiform and fingertip dermatitis. Especially chronic 
hyperkeratotic-raghadiform form can be clinically and histologically indistinguishable from 
palmoplantar psoriasis (Figure 3). 
 
Etiology of hand- and foot eczema can result from irritant- or allergic contact dermatitis, 
from atopic dermatitis or be multifactorial. The clinical picture may not correspond to etiol-
ogy.  
Contact sensitisation is found in less than 1/3 of all cases of hand eczema and may be the 
 
Figure 2. Subacute hand eczema with not sharply demarcated erythema and papulo-vesicular eruptions. 
  
Figure 3. Chronic hyperkeratotic-raghadiform palmoplantar eczema. 
Theoretical background 
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primary cause or complication to irritant or atopic hand eczema. Nickel, cobalt, fragrance-
mix, balsam of Peru and colophony are found to be the most common allergens in hand 
eczema [14].  
Concerning feet dermatitis, chromium compounds and adhesives are the most common 
cause of contact allergy [12]. 
1.3 Histology 
1.3.1 Healthy skin 
The skin can be divided into the epidermis- an outer layer and the dermis – an inner layer, 
which is attached and woven to the subcutaneous fat. The epidermis consists of different cell 
types of which epithelial cells (keratinocytes) are the most prominent in term of structural 
features. They can be divided into four layers: stratum basale, stratum spinosum (prickle cell 
layer), stratum granulosum and stratum corneum. Basal cells are undifferentiated cuboid 
cells with large nucleolus and basophilic cytoplasm. Prickle cells are polygonal with eosino-
philic cytoplasm and oval nuclei. Granular cell layer is characterised by keratohyalin gran-
ules. The cells of stratum corneum do not include the nuclei and are flattened. The epidermis 
renews itself continuously- the transit time of keratinocytes through the epidermis is esti-
mated at 56 days [15]. 
Dermis consists of collagen and elastic fibres 
as well as ground substance, and can be di-
vided into papillary (upper) and reticular 
(lower) layers. Dermis contains fibroblasts, 
neurovascular network and epidermal ap-
pendages, such as hair follicles, sebaceous- 
and sweat glands [16]. 
The blood supply in the skin follows 
throughout superficial- and deep vascular 
plexus, located respectively in upper- and 
lower reticular dermis. In contrast to richly vascularised papillary dermis, there are no capil-
laries in the epidermis and nutrition follows by diffusion [17]. 
Studies from the last three decades have shown that normal skin contains resident popula-
tions of dendritic cells, [18] as well as abundant amounts of T-lymphocytes, which can initi-
ate and maintain immune reactions without additional recruitment of T-cells from the 
blood  [19]. 
Skin from the soles and palms is characterised by a thickened stratum corneum and promi-
nent epidermal ridge pattern (Figure 4). There are no sebaceous glands and no hair follicles 
found in the palmoplantar localisation. 
Figure 4. Histology of the palmoplantar skin. 
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1.3.2 Psoriasis 
Classical psoriatic plaque lesions show 
regular acanthosis with elongated and 
club-shaped epidermal ridges. The su-
prapapillary plates are thinned. There is a 
loss or thinning of granular layer, in which 
terminal differentiation begins. Conse-
quently, incomplete, differentiated 
keratinocytes retaining a cell nucleus form 
a stratum corneum, which is known as con-
fluent parakeratosis. The papillary dermis 
is oedematous and includes tortuous and 
dilated capillaries. The latter cause visible 
redness of psoriatic efflorescence. The subpapillary dermis may include a perivascular mon-
onuclear infiltration, including T lymphocytes and dendritic cells. The diagnostic features of 
psoriasis lesions are "Munro microabscesses" – accumulated neutrophils within the 
parakeratotic stratum corneum. Another characteristic feature are "spongiform pustules of 
Kogoj", located beneath the stratum corneum and which consist of accumulated neutrophils 
[20]. The epidermal cell cycle is shortened in psoriatic skin to 7 days [21]. There is increased 
number of proliferating cells in the basal cell layer. 
Palmoplantar psoriatic lesions may cause diagnostic difficulties because of marked spongi-
osis. Stratum granulosum is usually normal or thickened in contrary to other localisations. 
The typical psoriatic pattern is often lacking [22].  
Histology of the palmoplantar psoriasis is represented in Figure 5. 
1.3.3 Contact dermatitis 
Contact dermatitis varies through all its stages including both dermal and epidermal 
changes. The main characteristic feature is the presence of intercellular oedema or spongiosis, 
which can lead to the formation of an intraepidermal vesicle or bulla. Another characteristic 
feature is exocytosis- lymphocytic infiltration of the epidermis. The epidermis is irregularly 
acanthotic with V-shaped rete ridges. There are multiple foci of parakeratosis and plasma in 
the parakeratosis. In contrast with psoriasis, stratum granulosum is preserved and there is 
no thinning of the suprapapillary plates and no oedema of the papillary dermis. In the pa-
pillary dermis, there is superficial perivascular lymphocytic infiltration, in some cases with 
numerous eosinophils. Vessels in the papillary dermis are often horizontal [23]. 
Spongiotic dermatitis can be divided into acute (with vesiculation and bullae), subacute 
(with marked acanthosis, spongiosis, vesiculation) and chronic (subtle spongiosis and pso-
riasiform acanthosis) [23]. Because a thickened stratum corneum at palmoplantar sites blis-
ters can be firm creating pompholyx. 
Figure 5. Histology of the palmoplantar psoriasis. 
Theoretical background 
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Histology of palmoplantar contact dermatitis is presented in Figure 6. 
 
1.4 Pathomechanism 
1.4.1 Psoriasis 
The exact etiology of psoriasis is still not completely understood. Psoriasis belongs to 
immune-mediated inflammatory diseases and has similarities in pathophysiology with 
rheumatoid arthritis, Crohn's disease, multiple sclerosis or juvenile-onset diabetes [24]. Pso-
riatic patients are known to have a higher prevalence of the metabolic syndrome [25] and an 
increased risk of cardiovascular events [26], which correlate with the severity of psoriasis. 
Psoriasis is believed to be result of complex interactions between T lymphocytes, keratino-
cytes and dendritic cells [24]. 
T cells play a crucial role in psoriasis and are polarised as Th1, Tc1 and Th17 cells. They 
release inflammatory cytokines (in case of Th1: INF-γ and TNF-α and in case of Th17: IL-17), 
which promote further recruitment of immune cells, keratinocyte proliferation, dermal an-
giogenesis and inflammation [24]. An innate immune system (including cytokines, chemo-
kines, antigen-presenting cells such as neutrophils and Langerhans' cells) also plays an im-
portant role in psoriasis by initiating and directing the acquired immune response and sup-
porting the epidermal hyperproliferation [27]. Chemokines produced by keratinocytes (in-
cluding IL-1, IL-23, Il-17, INF-γ) have an impact on both innate- and acquired immune sys-
tems and lead to activation of dendritic cells, neutrophils as well as T cells. Keratinocytes 
express also MHC-II and may act as non-professional APC [24,27]. 
1.4.2 Contact dermatitis 
Contact dermatitis results from the skin contact to the irritants (irritant contact dermatitis) 
or allergens (allergic contact dermatitis); in both cases by eventually coexisting atopy. These 
types of contact dermatitis are, in most cases, clinically and histological indistinguisha-
ble  [28]. 
The etiology of hand eczema is as followed: irritant contact dermatitis (35%), followed by 
 
Figure 6. Histology of the palmoplantar contact dermatitis: acute- (a) and subacute phase (b). 
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atopic (22%) and allergic hand eczema (19%) [29]. 
Pathomechanism of irritant contact dermatitis is an unspecific inflammatory reaction due to 
repeated chemical or physical irritation, which occurs only in the exposed skin [30]. 
In case of allergic contact dermatitis there are "allergen specific lymphocytes" that initiate the 
inflammation reaction. Through repeated contact with the allergens, the clinic aggravates 
and can spread out into the non-exposed skin [30]. 
Allergic contact dermatitis consists of an induction phase (known also as “afferent” or “sen-
sitising” phase) taking at least 4 days (but generally weeks to months) and effector (“effer-
ent”) phase taking from 1 to 4 days.  
In the induction phase, allergens (haptens) bind to antigen-presenting cells (epidermal Lang-
erhans cells). Activated Langerhans cells travel to regional lymph nodes, where they are rec-
ognised by specific T cells.  
Hapten presentation by Langerhans cells depends on the chemical nature of contact aller-
gens. Lipophilic haptens penetrate directly into Langerhans cells. They are processed in an 
“endogenous way”, favoring MHC class I molecules and are recognised by allergen-specific 
CD8+ T cells. Hydrophilic haptens (for example nickel ions) are processed in “exogenous 
way” favoring MHC class II molecules and activation of allergen-specific CD4+ T cells [31].  
Specific T-cells proliferate in lymph nodes and are released through efferent lymphatic ves-
sels into the circulation.  
The effector phase is caused by renewed contact to allergens and leads to clinical manifesta-
tion of allergic contact dermatitis. Allergen-specific effector T cells produce pro-inflamma-
tory cytokines, causing arrival of more inflammatory cells and promoting the killing of the 
haptenised cells [32]. Patch testing is a diagnostic procedure confirming allergic contact der-
matitis, in which positive results correspond to an “efferent” phase of allergic contact der-
matitis. 
1.5 Concept of “eczema in psoriatico” 
The concept of eczematous psoriasis has already been discussed by many authors. 
In 1991, Epstein et al. distinguished the primary and secondary eczematous psoriasis. The 
first was believed to be an endogenous process typical for regions such as the groin and axilla. 
The secondary eczematous psoriasis evolved as a result of exogenous factors such as irritants 
and allergens. According to this author, the diagnosis of eczematous psoriasis depends on 
the presence of stigmata of psoriasis [33]. 
Psoriasis in palmoplantar localisation may be influenced by different environmental factors. 
It is known, that allergic contact dermatitis can act as Koebner phenomena, maintaining or 
triggering palmoplantar psoriasis. This is why patch testing is often suggested as a standard 
examination in that localisation. Lack of responsiveness to psoriatic therapy can also be a 
manifestation of coexisting allergic contact dermatitis [34]. 
Theoretical background 
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Patients with palmoplantar psoriasis can develop due to household/environmental and/or 
occupational exposure contact dermatitis, although this is particularly rare. Consequently, 
such patients often present overlapping clinical and histological features of psoriasis and 
allergic contact dermatitis. 
The concept of “eczema in psoriatico” is illustrated in Figure 7 and 8. 
 
Figure 7. Relation between psoriasis, contact dermatitis,  
atopy and "eczema in psoriatico"(ep). 
 
 
Figure 8. Mechanism of development of "eczema in psoriatico". 
1.6 Summary 
The purpose of this chapter was to provide basic information regarding psoriasis and 
chronic contact dermatitis with focus on the particularities of the palmoplantar localisation. 
Epidemiology, morphology, histology and pathomechanism are described in subsections of 
this chapter. In order to facilitate the understanding of changes occurring in inflammatory 
diseases, detailed histology of palmoplantar healthy skin is enclosed. A new concept of “ec-
zema in psoriatico” and its development mechanism are discussed in conclusion. 
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2. Materials and methods 
This chapter provides characterisation of patients as well as detailed descriptions 
of allergy tests, histologic and immunohistologic procedures. In conclusion, the 
explanation of statistical methods follows.  
2.1 Patients 
Two experienced dermatopathologists performed a blind evaluation of 142 palmoplantar 
skin samples from patients treated in our department between 2000-2012 with a diagnosis of 
psoriasis, “eczema” or “eczema in psoriatico”. Clinical data, allergy tests were retrospec-
tively examined. Cases with chronic irritant non allergic hand and foot manifestation were 
excluded from this study and investigated separately. Patients with isolated atopic hand ec-
zema without contact allergy, as well as patients with palmoplantar pustular psoriasis, were 
not included in our study.  
59 patients and 63 skin samples were finally selected, in which both examiners had come to 
the same evaluation of the histopathological diagnoses: 30 patients and 33 skin samples with 
„eczema in psoriatico“, 13 patients with contact dermatitis, and 12 patients with psoriasis . 
In addition, five samples of healthy skin from 4 patients were selected as a control. Patients 
with marked positive epicutaneous patch tests results were accordingly classified.  
The presence of other classical skin lesions in typical distribution facilitates the diagnosis of 
psoriasis and contact dermatitis. By most of the cases (23/30 of “eczema in psoriatico”, 10/13 
of eczema), an isolated involvement of the palmoplantar skin existed. 
Tinea manum and pedum were excluded with additional mycological tests, as well as by 
negative PAS-staining. 
2.2 Allergy Tests 
All patients (except for control group and four psoriasis patients) were already investi-
gated with the patch test according to routine clinical examination. Patch tests were per-
formed to evaluate the skin sensitivity to standard allergens, such as potassium dichromate, 
thiuram mix, cobalt chloride, balsam of Peru, wool alcohols, nickel sulfate, PTBP resin, for-
maldehyde, fragrance mix, paraben mix, methyldibromo glutaronitrile, propolis, mercapto-
benzohiazole, fragrance mix II (according to DKG standards; producer Almirall Hermal). In 
some patients, another patch test screening series like: Cosmetics; Vehicles, Emulsifiers; Pre-
servatives; Disinfectants; Epoxy and Glues; Textile and Leather Dyes; Rubber Chemicals; 
Corticosteroids; Fragrance; Plants; Dental materials; Hairdressing; Cutting oil I (current); 
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Metal compounds were performed (data non presented). Patch tests were interpreted ac-
cording to International Contact Dermatitis Research Group [35] and were applied on the 
upper back and removed after 48 hours. Readings were carried out on day 2 (48 hours), on 
day 3 (72 hours), after 96 hours and additionally in doubtful cases on day 6 (144 hours). 
Additional allergy tests such as prick-tests and evaluation of total immunoglobulin E (IgE) 
were performed in some of the patients. Measurement of IgE in serum was based on fluores-
cence-enzyme immunoassay and investigated by UniCAP 250 EliA (Phadia). The scores 
were divided as followed: normal range under 100 kU/L, slight elevated between 100 and 
500 kU/L, moderate elevated between 500 and 1000 kU/L and strong elevated with more than 
1000 kU/L. 
2.3 Preparation of tissue samples 
Biopsies were obtained from patients seen at the Department of Dermatology and Vene-
reology, Otto-von-Guericke University in Magdeburg by routine dermato-pathological ex-
amination and after informed consent. Biopsies taken from the lesions were fixed in 4% neu-
tral buffered formaldehyde (Otto Fischar) and embedded in paraffin. All biopsies were cut 
and stained with hematoxylin-eosin (H&E) and periodic acid schiff (PAS). 
2.4 Analysis of the histological parameters in the stained sections with the 
hematoxylin-eosin technique 
According to our experience and to literature, we chose histological parameters that were 
considered helpful in the diagnosis of psoriasis and contact dermatitis. Evaluation of H&E- 
stained sections were done blinded without knowing clinical parameters or clinical diagno-
sis. Parakeratosis is graded as followed: mild, moderate and strong, occupying accordingly 
up to 33%, between 33 and 66% and more than 66% of whole stratum corneum. We evaluated 
the “distribution” of parakeratosis (multiple foci, confluent, para- and orthokeratosis verti-
cally distributed) and its content (only neutrophils, only plasma, or both neutrophils and 
plasma contemporary). Acanthosis and suprapapillary plates were measured with 10 mm 
scale under 10x fold amplification. Acanthosis was graded as followed: mild (less than 
3.33  mm), moderate (between 3.33 and 6.66 mm) and strong (with more than 6.66 mm). 
Thinning of the suprapapillary plates was considered when the ratio of thin rete ridges to 
the total rete ridges was equal or less than one-fifth. We evaluated loss or thinning of granu-
lar layer, lymphocytic exocytosis in epidermis, oedema of the papillary dermis and presence 
of "Munro microabscesses" and eosinophils in the infiltrate. The samples were divided ac-
cording to the shape of rete ridges (club-shaped, V-shaped or mixed) and capillaries in upper 
dermis (tortuous, dilated, horizontal or mixed). We measured the grade of spongiosis (lower 
part of epidermis, full-thickness, spongiotic vesicles) and the grade of infiltrate in upper der-
mis (mild, moderate or strong). 
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2.5 Immunochemistry 
The following primary antibodies were used: CK16 (clone: LL025; Abcam), CK17 
(clone:  E3; Dako), CD26 (polyclonal; Abcam), Filaggrin (clone: FLG01; Gene Tex Inc), TLR4 
(clone: 76B357.1; Abcam), MHC I (clone: EP1395Y; Abcam), MHC II (monoclonal; Abcam), 
CD1a (clone JPM30; Leica Biosystems), Ki67 (clone: MIB-1; Dako), CD4 (clone: 4B12; Bi-
oGenex), CD8 (clone:C8_144B; Dako), IL-8 (clone: 6217; R&D Systems), IL-17 (polyclonal; 
Abcam), IL-23 (polyclonal; Abcam), IL-31 (polyclonal; Abcam). 
Paraffine-embedded tissue sections were deparaffinised and rehydrated. 
The background staining was minimised through the following blocking methods: 10% FCS 
in DPBS (GIBCO, 14190-094) in case of CD26 and TLR 4; Protein Blocking Pro Taqs (BIOCYC, 
400104695) in case of MHC I, MHC II and IL-31 or combination of 0, 25% Tween in 10% FCS 
in PBS (Roth, 9127.1) and 10% FCS in PBS in case of IL-17. 
For antigen recovery in the case of CK16, Filaggrin, TLR4, IL-17, IL-23, IL-31, citrate buffer 
pH 6 (Zytomed, ZUC 028-500) were used or in case of CK17, CD26, MHC I, MHC II, CD1a, 
Ki67, CD4, CD8, IL-8, EDTA buffer pH 9 (Zytomed ZUC 029-500). 
Primary antibodies were diluted with DAKO REAL Antibody Diluent. 
Table 1. Characteristics of antibodies. 
Characteristics of primary antibodies as well as their dilution, incubation -time and -tem-
perature are summarised in the Table 1. 
Subsequent sections underwent the detection of primary antibodies followed through the 
secondary antibodies Streptavidin/ Biotin Systems (Zytomed Systems AP 125). 
Antibody Code 
Antigen 
retrival Dilution 
Incubation 
°C/time Description Source 
CK16 ab80574 citrate 1 to 500 20°C/30 min mouse monoclonal Abcam 
CK17 M7046 EDTA 1 to 100 37°C/45 min mouse monoclonal Dako 
CD26 ab28340 EDTA 1 to 500 20°C/30 min rabbit polyclonal Abcam 
Filaggrin GTX23137 citrate 1 to 100 37°C/45 min mouse monoclonal Gene Tex Inc. 
TLR4 ab22048 citrate 1 to 200 20°C/60 min mouse monoclonal Abcam 
MHC I ab52922 EDTA 1 to 1250 37°C/45 min rabbit monoclonal Abcam 
MHC II ab55152 EDTA 1 to 1200 37°C/45 min mouse monoclonal Abcam 
CD1a NCL-CD1a-220 EDTA 1 to 15 37°C/45 min mouse monoclonal Leica Biosystems 
Ki67 M724001 EDTA 1 to 100 37°C/45 min mouse monoclonal Dako 
CD4 AM421-5M EDTA Pure 37°C/45 min mouse monoclonal Bio Genex 
CD8 N159230 EDTA Pure 37°C/45 min mouse monoclonal Dako 
IL-8 MAB208 EDTA 1 to 200 4°C/overnight mouse monoclonal R&D Systems 
IL-17 ab79056 citrate 1 to 300 4°C/overnight rabbit polyclonal Abcam 
IL-23 ab115759 citrate 1 to 500 37°C/45 min rabbit polyclonal Abcam 
IL-31 ab37157 citrate 1 to 300 37°C/45 min rabbit polyclonal Abcam 
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2.6 Analysis of immunochemistry 
According to the literature [36], we distinguished normal-, linear-, dotted- and checkered 
filaggrin patterns. A “normal” pattern was considered if there was a strong staining includ-
ing 3-4 cell layers of stratum granulosum. Similar, but thinner staining was evaluated as a 
“linear” pattern. If there was an alternating positive and almost negative filaggrin expression 
it was described as “checkerboard-like" pattern. By most marked reduction of filaggrin it was 
estimated as a “dotted” pattern. The proportion of the stained cells were measured sepa-
rately in stratum corneum, stratum granulosum and stratum spinosum as followed: 0: no 
stained cells, 1: less than 25% stained cells, 2: between 25- and 50% stained cells and for 
3:  more than 50% stained cells. 
To assess epidermal staining of CK16, CK17, CD26, TLR4, IL-8, and MHC I, we used a 
semi-quantitative way of immunohistochemical evaluation presented by Chaiyarit et al. [37]. 
The epidermis was divided into three layers: basal, suprabasal (lower portion of prickle cell 
layer) and superficial (upper portion of prickle cell layer and stratum granulosum). Each 
layer was separately evaluated for the staining intensity and the proportion of immunoreac-
tive cells. Intensity of staining was as followed: 0= negative, 1= light, 2= moderate, 3= intense. 
The proportion of stained cells was graded as 0= if no stained cells, as 1 if there were less 
than 25% stained cells, as 2 if the stained cells were between 25- and 50% and 3 if there were 
more than 50% stained cells. To provide an immunostaining- intensity distribution (IID) in-
dex, the score of the staining intensity of every layer was multiplied by the score of the pro-
portion of stained cells in that layer. IL-8 was measured as already followed for basal, su-
prabasal, superficial layers and with the additional division of stratum corneum from super-
ficial layer. 
Dendritic cells (CD1a), CD4- and CD8- positive lymphocytes, MHC I- and MHC II- pos-
itive cells were semi-quantitatively evaluated by counting the number of positive cells in the 
skin in 3 consecutive high-power fields (HPF), separately in epidermis and in the upper half 
of dermis.  
IL-17, IL-23 and Il-31 were semi-quantitatively evaluated by counting the number of pos-
itive cells in the skin in 3 consecutive high-power fields (HPF) in dermis (in case of IL-17 
separately in the upper and in the lower half of dermis). 
Ki67 positive cells were counted under 10-fold magnification at the length of 10 mm in 
the whole epidermis and separately within: basal-, suprabasal- and superficial layer. 
2.7 Statistics 
The statistical analysis was carried out by the Institute for Biometry and Medical Infor-
matics at the Otto-von-Guericke University of Magdeburg. The analyses were done with the 
software IBM SPSS Statistics, Version 19 or 21. The outcome variables are described by their 
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frequencies or means and standard deviations in the different groups. Group comparisons 
of outcome variables were performed with chi-square tests or Mann-Whitney U tests, de-
pending on the characteristic scale. 
P-values were considered as followed: >0.1 no significance ns, ≤ 0.1 tendency (*), ≤ 0.05 sig-
nificance *, ≤ 0.01 high significance **, ≤ 0.001 highest significance ***. 
2.8 Summary 
Different procedures, including allergic tests, preparation of tissue samples as well as 
performance of immunohistologic stains with established and experimental antibodies were 
described in detail. 
Finally, precise methodology for quantitative comparison of histological and immunohisto-
logical stains was characterised. Tests used for statistical evaluation are explained in the con-
clusion. 
The results and their analysis will be presented in the following chapters.  
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3. Clinics and allergy tests 
Clinical diagnosis of palmoplantar skin changes, especially by isolated involve-
ment, remains difficult in many cases. Detailed clinical investigation of the whole 
skin and its derivatives may allow better classification. Allergy tests are neces-
sary for etiological classification of heterogeneous diseases, such as contact der-
matitis. 
3.1 Results 
3.1.1 Clinics 
59 patients out of 142 were finally se-
lected: 30 patients with „eczema in psori-
atico“, 13 patients with contact dermati-
tis, 12 with psoriasis and 4 patients with 
healthy skin as a control group. Selection 
was made after blind evaluation by two 
dermatopathologists, who were in ac-
cordance with the histological diagnosis. 
In the psoriasis group, there were 9 
women and 3 men, with a mean age of 55 
years (range 38-84 years). Among the pa-
tients with contact dermatitis, there were 5 women and 8 men, with a mean age of 47 years 
(range 29-75 years). The largest group with “eczema in psoriatico” consisted of 20 women 
and 10 men with a mean age of 45 years (range 18-74 years). The control group (with healthy 
skin) included 4 patients- 3 women and 1 man with a mean age of 56 years (range 31-80 
years). 
In 54%, biopsies were taken from palms (58% of “eczema in psoriatico”, 46% of contact der-
matitis, 75% of psoriasis) and in 46% from soles (42% of “eczema in psoriatico”, 54% of con-
tact dermatitis, 25% of psoriasis and in 100% of healthy skin samples). 
Some limitation of the study was due to retrospective analysis of clinical manifestations with 
the help of patients’ records. 
Most of the patients in the group of contact dermatitis and “eczema in psoriatico” have an 
isolated palmoplantar involvement. Clinical manifestation in other localisation was rarely 
observed. Skin changes at integument were seen in 23.3% in both: contact dermatitis and in 
 
Figure 9. “Eczema in psoriatico” with sharply demarcated  
erythematous plaques and slight scaling. 
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“eczema in psoriatico”. Scalp and nail involvement was observed only in “eczema in psori-
atico” (each one in 3.3%). In comparison, well-demarcated plaques with erythema and des-
quamation at the palms and/or soles were the only skin findings in 33.3% of patients with 
psoriasis. 66.6% of psoriasis-patients had other skin changes: 50% at integument, 8.3% at 
scalp and 25% at the nails.  
Detailed data presenting clinical manifestation in contact dermatitis, psoriasis and in “ec-
zema in psoriatico” is illustrated in Table 2.  
A clinical picture of “eczema in psoriatico” with sharp-demarcated erythematous plaques 
with slight scaling and fissuring is presented in Figure 9. 
3.1.2 Patch-tests 
Patch tests turned out to be positive (≥ +) in all patients with contact dermatitis and “ec-
zema in psoriatico” and in 55.6% of examined patients with psoriasis (5/9), as shown in Table 
3. Frequency of type-IV sensitisation in the group of contact dermatitis and “eczema in pso-
riatico” was statistically higher than in the group of psoriasis (in both cases p≤0.01). There 
were no statistical changes in the frequency of positive patch-test between contact dermatitis 
and “eczema in psoriatico”. Psoriasis patients with a weak patch-test reaction, did not show 
any clinical or histological correlate with contact hypersensitivity. 
Multiple type IV- sensitisations occurred more often than single type IV sensitisation and 
were observed in 69.2% of patients with contact dermatitis, 63.3% of patients with “eczema 
in psoriatico” and in all psoriasis patients with positive patch-tests.  
Strong positive test reactions (≥ ++/+++) were seen in 69.2% of patients with contact der-
matitis and in 63.3% of patients with “eczema in psoriatico” and in no patients with psoriasis.  
Strong positive-patch results were most often single; the ratio single versus multiple strong 
type IV- sensitisations were as followed: 5: 3 in a group of contact dermatitis and 4: 3 in the 
group of “eczema in psoriatico”. 
The most common positive allergen was nickel sulfate (34.6% of all examined patients), fol-
lowed by potassium dichromate and balsam of Peru (both 21.2%), cobalt chloride (19.2%), 
fragrance-mix I+II (15.7%) and formaldehyde (11.8%). Detailed analysis of the frequency of 
Clinical manifestation 
 
Contact 
dermatitis 
e 
n=13 
Psoriasis 
 
p 
n=9 
“Eczema in 
psoriatico” 
ep 
n=30 
Palmoplantar (isolated) 76.9% 33.3% 76.7% 
integument: 23.1% 50% 23.3% 
scalp: 0% 8.3% 3.3% 
nails: 0% 25% 3.3% 
Table 2. Clinical manifestation in contact dermatitis, psoriasis and "eczema in psoriatico". 
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the most common allergens is presented in Table 4.  
Allergies to nickel, cobalt, fragrances and balsam of Peru were observed mostly in women. 
Conversely, men were more often affected by an allergy to potassium dichromate and to 
formaldehyde. The sex ratio (women to men) in the groups allergic to following substances 
was as follows: 14: 3 for nickel sulfate; 5: 6 for potassium dichromate; 8: 3 for balsam of Peru; 
6: 4 for cobalt chloride; 6: 1 for fragrances and 2: 4 for formaldehyde.  
Strong, positive reactions (≥ ++/+++) were seen accordingly in 23.1% of all examined patients 
for nickel sulfate, in 15.4% for potassium dichromate, in 9.8% of all examined patients for 
cobalt chloride and formaldehyde and only in 2% patients for balsam of Peru. 
In the group of contact dermatitis, the most common allergen was formaldehyde. Positive 
reactions were strong (≥ ++/+++) in all of cases, and occurred in 30.7% of patients, affecting 
mostly men (75%). The second most common allergens in the group of contact dermatitis 
were nickel sulfate and potassium dichromate, with positive reactions in 15.4% of patients. 
In the group of “eczema in psoriatico”, the most common allergen was nickel sulfate. 
Every second patient (50%) showed a patch-positive reaction and every third (33.3%) a 
strong patch-positive reaction. The second most common allergen in the group of “eczema 
in psoriatico” was potassium dichromate, with 30% of allergy occurrence (and 23.3% with 
strong patch-positive reactions). The third most common allergens were cobalt chloride and 
balsam of Peru: in both cases, 23.3% of patients showed positive reactions (accordingly 16.7% 
and 3.3% of patients with strong reactions). In the group of “eczema in psoriatico” only 6.7% 
of patients were allergic to formaldehyde (3.3% suffered from a strong reaction). 
Illness 
 
Contact 
dermatitis 
e 
n=13 
Psoriasis 
 
p 
n=9 
“Eczema in 
psoriatico” 
ep 
n=30 
Type IV sensitisation (≥+): 100% 55.6% 100% 
Type IV sensitisation (≥++): 69.2% 0% 63.3% 
Single vs. multiple sensitisation (≥+): 4: 9 0: 5 9: 21 
Single vs. multiple sensitisation (≥++): 5: 3 0: 0 4: 3 
Table 3. Frequency of type IV sensitisation in contact dermatitis,  
psoriasis and in “eczema in psoriatico”. 
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In the group of psoriasis, there were only weak positive allergens. Type-IV sensitisation 
to thiuram mix, balsam of Peru und cosmetics (40% each) were more often than sensitisation 
to nickel sulfate, fragrance-mix, cobalt chloride and colophonium (20% each). 
3.1.3 IgE in serum 
Presence of IgE in serum was checked in 11 patients with contact dermatitis, in 5 patients 
with psoriasis and in 21 patients with “eczema in psoriatico”. The results are shown in Ta-
ble 5.  
IgE turned out to be in normal range in 81.8% patients with contact dermatitis, 60% with 
psoriasis and in only 23.8% of patients with “eczema in psoriatico”.  
Contact allergens Contact 
dermatitis 
e 
n=13 
Psoriasis 
 
p 
n=9 
“Eczema in 
psoriatico” 
ep 
n=30 
Nickel sulfate: 
≥ + 
 
≥ ++ 
 
15.4% 
 
15.4% 
 
11.1% 
 
0% 
 
50% 
 
33.3% 
Potassium dichromate: 
≥ + 
 
≥ ++ 
 
15.4% 
 
7.7% 
 
0% 
 
0% 
 
30% 
 
23.3% 
Balsam of Peru: 
≥ + 
 
≥ ++ 
 
15.4% 
 
0% 
 
22.2% 
 
0% 
 
23.3% 
 
3.3% 
Cobalt chloride: 
≥ + 
 
≥ ++ 
 
15.4% 
 
0% 
 
11.1% 
 
0% 
 
23.3% 
 
16.7% 
Fragrance-mix I+II: 
≥ + 
 
≥ ++ 
 
15.4% 
 
7.7% 
 
11.1% 
 
0% 
 
16.7% 
 
6.7% 
Formaldehyde: 
≥ + 
 
≥ ++ 
 
30.7% 
 
30.7% 
 
0% 
 
0% 
 
6.7% 
 
3.3% 
Table 4. The most common allergens and their frequency in contact dermatitis,  
psoriasis and in “eczema in psoriatico”. 
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Slightly elevated IgE levels in serum were detected in 18.2% of patients with contact derma-
titis, in 20% of examined patients with psoriasis, and in 52.4% of examined patients with 
“eczema in psoriatico”. Moderately- and strongly elevated IgE values were found in accord-
ingly 9.5 and 14.3% of patients with “eczema in psoriatico” and in one patient with psoria-
sis  (20%). 
3.2 Discussion  
3.2.1 Clinics 
Patients dealing with sharply demarcated scaling erythema on hands and feet should be 
examined carefully. The existence of other skin changes may facilitate the clinical diagnosis. 
Just single, sharply demarcated erythrosquamous plaques, for example on elbows and knees, 
or erythema with fissuring in the anal cleft, erythematous plaques with scaling on scalp, oil 
spots or onycholysis can help to diagnose psoriasis. Positive history of arthritis affecting ter-
minal joints of the fingers and toes, spondylitis, sacroilitis, tendinitis can assist the diagnosis 
of psoriatic arthritis. 
On the other hand, pruritic papular- and vesicular- eruptions on erythematous ground or 
lichenification, non-sharply demarcated erythematous plaques with slight scaling, fissures 
and excoriations are characteristic for contact dermatitis.  
Nail pitting, it can occur in both psoriasis and eczema. Isolated scaling on the scalp may be 
a manifestation of pityriasis capitis.  
Positive history of psoriasis does not exclude coexistence of contact dermatitis or atopy or 
irritation. Hands and feet are exposed to different mechanical and environmental factors. 
The detailed diagnostic inclusive patch testing is essential for right diagnosis and successful 
treatment. 
In the examined group of “eczema in psoriatico” and allergic chronic contact dermatitis, over 
70% of patients had isolated palmoplantar skin changes. Isolated palmoplantar lesions were 
also found in every third examined patient with psoriasis. Clinical diagnosis by isolated skin 
IgE in serum 
 
Contact 
dermatitis 
e 
n=11 
Psoriasis 
 
p 
n=5 
“Eczema in 
psoriatico” 
ep 
n=21 
Negative (<100): 81.8.% 
 
60% 
 
23.8% 
 
Positive (>100) 18.2% 40% 76.2% 
Slight elevated (100-500): 18.2% 
 
20% 
 
52.4% 
 
Moderate elevated (500-1000): 
 
0% 
 
0% 
 
9.5% 
 
Strong elevated (>1000): 
 
0% 
 
20% 
 
14.3% 
 
Table 5. IgE values in serum of patients with contact dermatitis,  
psoriasis and "eczema in psoriatico". 
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changes remains difficult in many cases. In our study, the final diagnosis was based on clinics, 
histologic patterns and results of allergy tests as well as on past medical history. 
3.2.2 Patch-tests 
Our study was retrospective; a detailed evaluation of clinical significance of type IV sen-
sitisation was limited.  
One of the inclusion criteria in the group of contact dermatitis and “eczema in psoriatico” 
was at least one positive reaction in the patch test. This is why the frequency of sensitisation 
to different allergens in our patients was higher compared to the data found in the literature. 
Cases with chronic irritant contact dermatitis and irritant “eczema in psoriatico” without 
contact sensitisation were excluded from this study and examined separately. 
37 of 59 examined patients were women. Only in the group of contact dermatitis, there was 
the predominance of men over women (8: 5). The sex ratio may have been influenced, due 
to different occupational- and domestic factors, the frequency of positive patch-test reactions 
in groups of “eczema in psoriatico”, contact dermatitis and psoriasis.  
According to the literature, the most common contact allergens are nickel, fragrances and 
thiomersal [6,38]. In our study, sensitisation to metals (nickel, chromate, cobalt), as well as to 
balsam of Peru, fragrances and formaldehyde were observed most often. There were some 
differences in the frequency of positive patch tests in groups of “eczema in psoriatico”, con-
tact dermatitis and psoriasis.  
Nickel is the most common allergen. Estimated incidence of nickel allergy accounts for about 
8.6% among the whole population [6] and between 20 and 30% among patch tested patients 
[39]. Due to an increased exposure to nickel-releasing jewellery and to wet works, women 
are affected by nickel allergy 3-10 more frequently than men [6]. In our study, type IV sensi-
tisation to nickel was found in 34.6% of all examined patients (14 women and 2 men), ac-
cordingly in 50% with “eczema in psoriatico”, 15.4% with contact dermatitis and 11.1% with 
psoriasis. These differences can probably be connected with the sex ratio (the group of “ec-
zema in psoriatico” was represented mostly by women and of contact dermatitis mostly by 
men). Nickel sensitisation occurred in 68.75% as multiple allergies, usually with other metals. 
Nickel allergy may cause or trigger hand eczema by different pathogenic mechanisms [39], 
especially in women [40]. Hand eczema due to nickel sensitisation can result from occupa-
tional or domestic exposure, or be part of systemic allergic contact dermatitis[39] . Skin bar-
rier diseases due to filaggrin-loss-of-function mutations may be also an important endoge-
nous factor related to sensitisation to nickel [41].  
The chromate allergy is estimated between 3.1 and 10.5% [42]. In our study, 21.6% of all 
patients had positive patch tests to potassium dichromate. Chromate allergy can be acquired 
due to the occupational exposure, especially in the building and machine industry. Although 
cement is the most common source of chromate allergy, its frequency is decreasing due to 
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legislation regulating the concentration of hexavalent chromate in ready-to-use cement (in 
Denmark since 1981, in the EU since 2003)[42]. Due to this legislation, the sex ratio of the 
chromate allergy is changing. For example, the chromate allergy in Denmark is nowadays 
more often observed in women than in men, possibly due to chrome-tanned leather in gloves 
and shoes [42]. In our study, chromate sensitisation was observed in 6 men and in 5 women, 
in all cases as multiple allergies. In 8 of 11 patients allergic to potassium dichromate, there 
was, probably due to occupational exposures, contemporary sensitisation to nickel and/or 
cobalt. The average age of patients with chromate allergy was 42.7 (18 to 60 years). Chromate 
allergy was observed in 30% patients with “eczema in psoriatico” mostly as co-sensitisation 
to other metals and in 15.4% patients with contact dermatitis. Chromate allergy is of clini-
cally significance and can trigger or cause therapy-resistant hand- and foot eczema. 
Cobalt is used in manufacturing alloys. The coexistence of a nickel- and cobalt allergy 
can be explained by the occurrence of both metals in nature [43]. The frequency of cobalt 
allergy was estimated between 1-3% of adults. In our study, positive patch tests to cobalt 
were observed in 19.2% of examined patients; 4 men and in 6 women with an average age of 
38.9 years (from 21 to 74 years). Cobalt sensitisation was diagnosed more often in “eczema 
in psoriatico” (23.3%) than in contact dermatitis (15.4%) or psoriasis (11%). Cobalt allergy 
occurred in our cases often in association with a positive test to nickel sulfate (60%) or potas-
sium dichromate (50%) or to both of them (40%). 
Formaldehyde is used as disinfectant and preservative agent in the food- and metal 
working industry, as well as a disinfectant in medical sector. Formaldehyde belongs to clin-
ically significant allergens in occupational hand eczema. In Germany, 2% of patch tested pa-
tients with contact dermatitis showed an allergy to formaldehyde. In comparison, the sensi-
tisation rate to formaldehyde in USA and Canada is higher and estimated between 5 and 10% 
[44]. Sensitisation to formaldehyde was observed in 11.7% of our patients. Surprisingly, for-
maldehyde turned out to be the most common allergen in the group of contact dermatitis 
affecting 30.7% of patients, in 75% of men. 
Sensitisation to balsam of Peru (which may indicate fragrance allergy) and to fragrances was 
observed accordingly in 21.6% and 15.7% of all examined patients and was rarely strong 
(accordingly 2% and 5.7%). Allergy to fragrances and balsam of Peru develops often in course 
of chronic diseases due to application of various “ointments” with sensitising potential. 
There are conflicting results between correlation of psoriasis and contact sensitivity. 
Bansgaard et al. observed an inverse relationship between psoriasis and contact allergy [45]. 
The results based on register study with 15461 patch-tested patients (806 patients of 15461 
suffered from psoriasis). The authors did not evaluate the influence of the site of lesions or 
the disease's duration. Moss et al. [46] showed, that patients with psoriasis were less respon-
sive to sensitisation with DNCB than healthy controls. On the other hand, other authors re-
ported higher incidence of type IV sensitisation in palmoplantar psoriasis than in psoriasis 
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without palmoplantar involvement [47]. For example, Caca-Biljanovska et al. observed pos-
itive-patch tests in 39.5% of 38 patients with palmoplantar psoriasis versus 12.7% of 63 pa-
tients with psoriasis vulgaris without palmoplantar localisation [48]. In some other studies, 
there were no differences between the frequencies of type IV sensitisation in psoriasis pa-
tients due to the site of lesions. In the group of 305 patients with psoriasis examined by Barille 
et al. [49], 24% showed at least one positive patch-tests reaction, of which 22.4% of 80 patients 
with palmoplantar involvement. Malhotrat et al. [50] examined 200 patients with psoriasis. 
At least one positive patch-test reaction was observed in 21.6% of them. The frequency of 
positive patch tests correlated with the disease's duration. In this study, the site of lesions 
did not show any relationship with the positivity of patch-tests. Patch-test positivity was 
observed mostly in cases of topical medicaments or fragrances.  
We believe that patch-testing is mandatory in all cases with palmoplantar psoriasis. In 
our study, there were only 9 patch test- examined patients with psoriasis. Every second 
showed weak positive reaction without clinic and histological changes characteristic for ec-
zema. It can be speculated, that in the predisposed patients with psoriasis type IV sensitisa-
tion can lead to additional development of contact dermatitis, which we call “eczema in pso-
riatico”.  
3.2.3 IgE levels in serum 
Atopy is known to be an important risk factor for the development and maintenance of 
chronic hand eczema. The elevated total IgE levels in serum have a positive predictive value 
for diagnosis of atopy. 
Inflammation seen in atopic disorders is determined by type 2 Th cells in contrary to psori-
asis which is determined by Th-17 and Th-1 cells. Both Th-1 and Th-2 T cells are assumed to 
antagonise each other on a cytokine level [51,52]. Patients with Th-1 mediated diseases were 
found to have a lower prevalence of atopy [53]. A recent study of Hajdarbegovic et al. [54] of 
448 patients, confirmed a reduced prevalence of atopic disorders only in the case of psoriatic 
arthritis but not in psoriasis vulgaris.  
Measurement of IgE levels in serum was performed in 37 of 59 patients. The results were 
collected from the medical records of examined patients. Due to the retrospective aspect of 
our study, detailed evaluation of self-reported symptomatology of atopic disorders (ie, hay 
fever, asthma) was limited.  
Patients with “eczema in psoriatico” showed a higher frequency of elevated IgE levels in 
serum compared to patients with contact dermatitis and psoriasis. It can be concluded that 
patients with psoriasis with coexisting atopy can develop easier contact sensitisation and in 
consequence “eczema in psoriatico”. The role of atopy in the developing of “eczema in pso-
riatico” needs further clarification. 
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3.3 Summary 
Clinical diagnosis remains difficult by isolated palmoplantar involvement. This chapter 
has given an overview of the differences in clinical manifestations between contact dermati-
tis, psoriasis and “eczema in psoriatico”. The frequency of contact sensitisation and detailed 
analysis of the most frequent allergens in all three groups have been studied precisely. The 
potential role of atopy is discussed at the end of the chapter.  
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4. Histology 
Histological differentiation between psoriasis and chronic contact dermatitis in 
palmoplantar localisation may be troublesome. Distinguishing a new entity “eczema in 
psoriatico” allows a better histological classification. The first part of this chapter com-
prises of the description of histological features found in contact dermatitis, psoriasis and 
in “eczema in psoriatico” and the second, their detailed analyses. 
4.1 Results histology 
The frequency of different histological features in contact dermatitis, psoriasis, “eczema 
in psoriatico” and in healthy skin are shown in Table 6 and 7. 
In the grade of parakeratosis, there were statistical differences between contact dermatitis 
and psoriasis and between contact dermatitis and “eczema in psoriatico”. Mild parakeratosis 
was a common feature in contact dermatitis 85% (11/13) and was less often seen in psoriasis 
and “eczema in psoriatico”-in both groups in 33%. Moderate and heavy parakeratosis were 
more often in psoriasis (accordingly 25% and 42%) and in “eczema in psoriatico” (accord-
ingly 36% and 30%) and not seen in contact dermatitis.  
Multiple foci of parakeratosis were found to be more common in contact dermatitis 77% 
(10/13) than in “eczema in psoriatico” 33% (11/33) and were not found in psoriasis 0% (0). 
Vertically distributed parakerathosis and orthokeratosis were more often seen in psoriasis 
patients 58% (7/12) than in “eczema in psoriatico” 15% (5/33) and were not observed in con-
tact dermatitis 0% (0). Confluent parakeratosis was more common in “eczema in psoriatico” 
52% (17/33) and in psoriasis 42% (5/12) and was rarely observed in contact dermatitis 8% 
(1/13).  
A typical histological characteristic of psoriasis was neutrophils found in parakeratosis 92% 
(11/12), rarely observed in “eczema in psoriatico” 15% (5/33) and in contact dermatitis 8% 
(1/13). Neutrophils and exsudation both occurring in parakeratosis were a common finding 
in “eczema in psoriatico” 85% (28/33) and in contact dermatitis 62% (8/13) in contrary to 
psoriasis 8% (1/12). Isolated exsudation in parakeratosis was rarely found in contact derma-
titis 15% (2/13) and was not observed in psoriasis and in “eczema in psoriatico”. 
There were no statistical differences in grade of acanthosis between psoriasis, contact der-
matitis and “eczema in psoriatico”. Most of the slides showed moderate acanthosis- accord-
ingly 77% of contact dermatitis, 83% of psoriasis and 85% of “eczema in psoriatico”. 
Regular acanthosis was more frequent in psoriasis 83% (10/12) followed by mixed pattern 
17% (2/12). In contrast, irregular acanthosis was found to be more common in contact der-
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matitis 69% (9/13). In “eczema in psoriatico” regular acanthosis was found with similar fre-
quency as mixed pattern- accordingly 52 and 48%. 
Loss or thinning of the whole granular layer was found more often in psoriasis 42% (5/12) 
and in “eczema in psoriatico” 33% (11/33) and rarely in contact dermatitis 15% (2/13). Partial 
loss of the granular layer was seen more often in “eczema in psoriatico” 61% (20/33), followed 
by psoriasis 33% (4/12) and contact dermatitis 15% (2/13). Thinning of the suprapapillary 
plates was often observed in psoriasis and in “eczema in psoriatico” accordingly in 67 and 
in 85%, whereas it was a less common feature in contact dermatitis 8% (1/13). 
Isolated club-shaped rete ridges were frequent seen in psoriasis 92% (11/12), less frequent in 
“eczema in psoriatico” 46% (21/46) and were not seen in contact dermatitis 0% (0). Isolated 
V-shaped rete ridges was rarely seen and found only in contact dermatitis 8% (1/13). Mixed 
pattern combining club-shaped and V-shaped rete ridges was dominating in contact derma-
titis 92% (12/13) and in “eczema in psoriatico “60% (20/33) in contrary to psoriasis, only 
8%  (1/12). 
Mild spongiosis in the lower part of epidermis was a common finding in healthy palmoplan-
tar skin 80% (4/5), in contrary to “eczema in psoriatico”, contact dermatitis and psoriasis- 
accordingly 18, 23 and 25%. Full-thickness spongiosis was observed in 45% of “eczema in 
psoriatico” cases (15/33) and in 23% of contact dermatitis, and was not seen in any psoriasis 
skin samples. Spongiotic vessels were often found in contact dermatitis 54% (7/13), less often 
in “eczema in psoriatico” 36% (12/33) and were lacking in psoriasis. 
Typical finding of contact dermatitis and of “eczema in psoriatico” was lymphocytic exocy-
tosis in epidermis (both 100%) in contrary to psoriasis with only 25% (3/12). 
Eosinophiles were rarely seen in “eczema in psoriatico” 12% (4/33) and in contact dermatitis 
23% (3/13) and were lacking in psoriasis and in healthy skin. 
Tortuous or dilated capillaries in the upper epidermis were typical findings in psoriasis 
(100%), and were seen less frequently in “eczema in psoriatico” 45% (15/33) and in contact 
dermatitis 23% (3/13). Horizontal vessels were a frequent finding in contact dermatitis 54% 
(7/13), whereas it was rarely seen in “eczema in psoriatico”: 9% (3/33). Mixed patterns com-
bining tortuous, dilated and horizontal vessels were observed in 45% of “eczema in psori-
atico” cases (15/33) and in 23% of contact dermatitis (3/13). Oedema of papillary dermis was 
present in 67% (8/12) of patients with psoriasis, in 76% (25/33) of patients with “eczema in 
psoriatico”, whereas it was a less common feature in patients with contact dermatitis: 15% 
(2/13). All slides were negative in PAS staining. 
Typical histological features of “eczema in psoriatico” were vertically para- and othokerato-
sis, parakeratosis with neutrophils and plasma, regular acanthosis, loss of granular layer, 
thinning of suprapapillary plates, lymphocytic exocytosis and spongiosis, which are pre-
sented in Figure 10.   
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Histologic 
features 
Contact 
dermatitis 
e 
n=13 
Psoriasis 
 
p 
n=12 
Eczema in 
psoriatico 
ep 
n=33 
Healthy 
skin 
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e vs p 
P-value 
 
ep vs e 
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ep vs p 
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Parakeratosis: 
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0% 
 
0% 
 
33% 
 
25% 
 
42% 
 
33% 
 
36% 
 
30% 
 
0% 
 
0% 
 
0% 
 
 
** 
 
 
*** 
 
 
ns 
 
  
*** 
Parakeratosis: 
multiple foci 
 
confluent 
 
Para-
/orthokeratosis v. 
 
77% 
 
8% 
 
0% 
 
0% 
 
42% 
 
58% 
 
33% 
 
52% 
 
15% 
 
0% 
 
0% 
 
0% 
 
 
*** 
 
 
** 
 
 
** 
 
 
*** 
Parakeratosis: 
with neutrophils 
 
with plasma 
 
neutrophils & 
plasma 
 
8% 
 
15% 
 
62% 
 
92% 
 
0% 
 
8% 
 
15% 
 
0% 
 
85% 
 
0% 
 
0% 
 
0% 
 
 
*** 
 
 
(*) 
 
 
*** 
 
 
*** 
Acanthosis: 
mild 
 
moderate 
 
strong 
 
23% 
 
77% 
 
0% 
 
0% 
 
83% 
 
17% 
 
6% 
 
85% 
 
9% 
 
80% 
 
20% 
 
0% 
 
 
ns 
 
 
ns 
 
 
ns 
 
 
** 
Acanthosis: 
regular 
 
irregular 
 
mixed 
 
0% 
 
69% 
 
31% 
 
83% 
 
0% 
 
17% 
 
52% 
 
0% 
 
48% 
 
0% 
 
100% 
 
0% 
 
 
*** 
 
 
*** 
 
 
(*) 
 
 
*** 
Table 6. Histologic features: evaluation of type and grade of parakeratosis and acanthosis. ns nonspecific, (0)>0,1 no 
significance, (*) ≤ 0.1 tendency, * ≤ 0.05 significance, **≤ 0.01 high significance, ***≤ 0.001 highest significance. 
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Histologic features 
Contact 
dermatitis 
e 
n=13 
Psoriasis 
 
p 
n=12 
Eczema in 
psoriatico 
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n=33 
Healthy 
skin 
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P-value 
 
e vs p 
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ep vs e 
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ep vs p 
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Loss/thinning of 
granular layer: 
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69% 
 
15% 
 
15% 
 
 
25% 
 
42% 
 
33% 
 
 
6% 
 
33% 
 
61% 
 
 
100% 
 
0% 
 
0% 
 
 
(*) 
 
 
*** 
 
 
ns 
 
  
*** 
Thinning of the 
suprapapillary plates: 
8% 67% 85% 0% ** *** ns *** 
Rete ridges: 
club-shaped 
 
V-shaped 
 
mixed 
 
0% 
 
8% 
 
92% 
 
92% 
 
0% 
 
8% 
 
39% 
 
0% 
 
61% 
 
0% 
 
80% 
 
20% 
 
 
*** 
 
 
** 
 
 
** 
 
 
*** 
Lymphocytic exocytosis 
in epidermis 
100% 25% 100% 0% *** ns *** *** 
Capillary in upper 
dermis: 
tortuous/ dilated 
 
horizontal 
 
mixed 
 
23% 
 
54% 
 
23% 
 
100% 
 
0% 
 
0% 
 
45% 
 
9% 
 
45% 
 
0% 
 
40% 
 
60% 
 
 
*** 
 
 
** 
 
 
** 
 
 
(*) 
Spongiosis: 
none 
 
full-thickness 
 
lower part of epidermis 
 
spongiotic vesicels 
 
0% 
 
23% 
 
23% 
 
54% 
 
75% 
 
0% 
 
25% 
 
0% 
 
0% 
 
45% 
 
18% 
 
36% 
 
20% 
 
0% 
 
80% 
 
0% 
 
 
 
*** 
 
 
 
ns 
 
 
 
*** 
 
 
 
*** 
Infiltrate in upper 
dermis: 
mild 
 
moderate 
 
strong 
 
15% 
 
77% 
 
8% 
 
42% 
 
58% 
 
0% 
 
12% 
 
76% 
 
12% 
 
100% 
 
0% 
 
0% 
 
 
ns 
 
 
ns 
 
 
ns 
 
 
*** 
Oedema of the papillary  
dermis 
15% 67% 76% 0% * *** ns * 
Table 7. Histologic features: evaluation of loss/thinning of granular layer, thinning of the suprapapillary plates, form of rete 
ridges and of capillaries in the upper dermis, lymphocytic exocytosis in epidermis, spongiosis, infiltrate in upper dermis and 
oedema of the papillary dermis  ns nonspecific, (0)>0.1 no significance, (*) ≤ 0.1 tendency, * ≤ 0.05 significance, **≤ 0.01 high 
significance, ***≤ 0.001 highest significance. 
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Figure 10. “Eczema in psoriatico” (a and b) with parakeratosis containing both neutrophils and plasma,regular acanthosis, 
loss of granular layer, thinning of suprapapillary plates, lymphocytic exocytosis and spongiosis. 
4.2 Discussion histological results 
In the literature, there are a few studies comparing histologic features of non-pustular 
palmoplantar psoriasis with palmoplantar contact dermatitis [55,56]. It is well known, that 
histological differential diagnosis between these both diseases in palmoplantar localisations 
may be troublesome or even impossible. 
In our study, distinguishing a new group of patients with the diagnosis of “eczema in psori-
atico” (which enclosed patients with overlapping histological features of both psoriasis and 
contact dermatitis) enabled easier differentiation between typical palmoplantar psoriasis 
and typical palmoplantar contact dermatitis. 
Statistically significant histological features useful in diagnosing of palmoplantar psoriasis 
were in our study: regular acanthosis (p≤0.001), club shaped rete ridges (p≤0.001), thinning 
of suprapapillary plates (p≤0.01), neutrophils in parakeratosis (p≤0.001), tortuous and dilated 
capillaries in upper dermis (p≤0.001), oedema of papillary dermis (p≤0.05) and presence of 
Munro microabscesses (p≤0.001). Loss or thinning of granular layer, known to be typical for 
psoriasis, was more frequent in psoriasis than in contact dermatitis, but occurred only par-
tially in many cases. 
The features helpful for diagnosis of palmoplantar contact dermatitis were in our cases: ir-
regular acanthosis (p≤0.001), multiple foci of parakeratosis (p≤0.001), lymphocytic exocytosis 
in epidermis (p≤0.001) and horizontal vessels in upper dermis. Full-thickness spongiosis and 
spongiotic vesicels were also considered in favour of contact dermatitis. Isolated plasma 
exsudation in parakeratosis was rarely observed (15%) and in most of the cases (62%) oc-
curred in combination with neutrophils. Isolated V-shaped rete ridges, known to be typical 
for contact dermatitis, were not a common finding in our cases in contrary to mixed patterns 
combining club-shaped- and V-shaped- rete ridges. 
“Eczema in psoriatico” showed overlapping histological features with both psoriasis and 
contact dermatitis. The following histological findings of “eczema in psoriatico” were shared 
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with psoriasis: moderate to strong parakeratosis, regular acanthosis, loss or thinning (also 
partially) of granular layer, thinning of suprapapillary plates, oedema of papillary dermis 
and presence of Munro microabscesses. The following features of “eczema in psoriatico” 
were shared with contact dermatitis: neutrophils and plasma exsudation in parakeratosis, 
lymphocytic exocytosis in epidermis, full-thickness spongiosis or formations of spongiotic 
vessels. 
Parakeratosis and orthokeratosis vertically distributed were typical for psoriasis, absent in 
contact dermatitis, but rarely seen in “eczema in psoriatico” (15%). Rete ridges in “eczema 
in psoriatico” differed from both psoriasis and contact dermatitis showing mixed patterns 
(61%) or isolated club-shaped patterns (39%). Capillaries in upper dermis showed with the 
same frequency tortous/ dilatated shape or mixed pattern combining tortous/ dilatated- and 
horizontal- vessels. Eosinophiles in upper dermis were a rare histological feature observed 
only in contact dermatitis and in “eczema in psoriatico” and showed no statistical signifi-
cance. Grade of acanthosis and of infiltrate in upper dermis also showed no statistical differ-
ences between psoriasis, contact dermatitis and “eczema in psoriatico” in palmoplantar lo-
calisation.  
Similar to previous observations [47,55], we detected spongiosis in some psoriasis samples. 
In contrary to other studies, (Aydin et al. [55]: spongiotic vesicles in 76.5% of examined 
palmoplantar psoriasis), we observed in every fourth patient with psoriasis, mild spongiosis 
located in lower part of epidermis. Surprisingly, this finding was also noticed in 80% of 
healthy skin samples. 
4.3 Summary 
Histological evaluation of palmoplantar lesions was a relevant part of this study. The first 
section focused on the analysis and quantitative comparison of histological parameters that 
were considered helpful in the diagnosis of psoriasis and contact dermatitis.  
According to our results, which are discussed in the second section, it was possible to 
distinguish distinctive patterns characteristics for contact dermatitis, psoriasis or “eczema in 
psoriatico” just in H&E stains. “Eczema in psoriatico” showed overlapping histological fea-
tures with both psoriasis and contact dermatitis. 
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5. Immunohistology 
For a better understanding of pathomechanism of “eczema in psoriatico”, differ-
ent immunohistological stainings were performed. We focused on alternations in 
epidermal differentiation, acquired and innate immunity. 
5.1 Results immunohistology 
5.1.1 Filaggrin 
The frequency of different filaggrin patterns varied in all diseases from one another. As 
expected, healthy skin controls showed a strong filaggrin staining with the positivity of 3-4 
layers of stratum granulosum. 
“Eczema in psoriatico” had the most reduced filaggrin expression with accordingly 42.4% of 
“dotted”-, 33.3% of “checkered”-, 21.2% of “linear”- and only 3% per cent of “normal”- stain-
ing. In the psoriasis group, a down-regulated filaggrin expression was less prominent, with 
accordingly 50% of “linear”- and 25% of “checkered”- and 16.7% of “normal” staining. In the 
group of contact dermatitis, the filaggrin alterations were only slightly reduced: the “lin-
ear“pattern (46.2%) was followed by “normal” staining (38.5%). Distribution of filaggrin pat-
terns in “eczema in psoriatico”, contact dermatitis, psoriasis and in healthy skin are pre-
sented in Figures 11 and 12. The evaluation of distribution of filaggrin patterns in patients 
without elevated IgE in serum did not reveal any significant differences in comparison to 
foregoing assessment. In those cases, “eczema in psoriatico” also turned out to have the most 
reduced filaggrin expression compared to contact dermatitis (p≤0.01) and psoriasis (p≤0.5). 
 
Figure 11. Filaggrin patterns distribution in 
“eczema in psoriatico” (ep) contact dermatitis (e), psoriasis (p) and in healthy skin (c). 
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There were no statistical differences between psoriasis and contact dermatitis. 
 
Figure 12. Filaggrin patterns: ”dotted” in “eczema in psoriatico” (ep),“ linear” in contact dermatitis (e), 
 “checkered” in psoriasis (p) and “normal” in healthy skin (c). 
The evaluation of proportion of the positive stained cells showed statistically differences 
in stratum spinosum (Figure 13). Psoriasis turned out to have more positive stained cells as 
“eczema in psoriatico” (p≤0.01) and allergic contact dermatitis (p≤0.5).  
 
Figure 13. Filaggrin staining within stratum spinosum in "eczema in psoriatico"(ep), contact dermatitis (e),  
psoriasis (p) and in healthy controls (c). 
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5.1.2 Cytokeratines 16 and 17 (CK16, CK17) 
As presented in Figure 14 and 15, positive CK16 staining with diffuse patterns was ob-
served in suprabasal- and superficial- epidermis layers of all examined inflammatory dis-
eases (ep, e, p) and was absent in healthy skin (c). There were no statistical differences be-
tween psoriasis, contact dermatitis and “eczema in psoriatico” (all three similarly highly pos-
itive) in contrary to healthy skin samples (negative staining with except to positive 
acrosyryngium) (p≤0.001). 
 
Figure 14. CK16 in "eczema in psoriatico"(ep), contact dermatitis (e),  
psoriasis (p), and in healthy skin (c), accordingly in suprabasal- and superficial layers . 
 
Figure 15. CK16 in “eczema in psoriatico” (ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
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CK17 staining was found to be negative in basal- and positive in suprabasal- and in su-
perficial- epidermis layers of all examined inflammatory diseases (ep, e, p). Healthy controls 
(c) showed negative staining in the whole epidermis. Strong positive reactions were observed 
in “eczema in psoriatico” and psoriasis in upper suprabasal- and in superficial- layers in 
contrary to weak positive staining in contact dermatitis (accordingly p≤0.01 in suprabasal 
layer, p≤0.001 in superficial layer comparing “eczema in psoriatico” and contact dermatitis). 
There were no statistical differences between “eczema in psoriatico” and psoriasis. All results 
are illustrated in Figure 16 and 17. 
 
Figure 16. CK17 in "eczema in psoriatico" (ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c) in suprabasal- und superficial layers. 
 
Figure 17. CK17 in “eczema in psoriatico” (ep), contact dermatitis (e), 
 psoriasis (p) and in healthy skin (c). 
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5.1.3 Dipeptidyl peptidase IV (CD26) 
CD26 staining showed a positive reaction in the whole epidermis of all examined inflam-
matory diseases, as presented in Figure 18 and 19. In health controls, weak positive reactions 
were observed in basal- and suprabasal layers. There were no statistical differences between 
“eczema in psoriatico”, allergic contact dermatitis and psoriasis in basal keratinocytes (all 
slides showed up-regulated CD26 expression compared to healthy controls). Psoriasis slides 
had stronger staining compared to “eczema in psoriatico” in suprabasal- (p≤0.05) and super-
ficial layers (p≤0.01). There were no statistical differences in the CD26 staining between “ec-
zema in psoriatico” and allergic contact dermatitis. 
 
Figure 18. CD26 with overexpressed staining in suprabasal- and superficial layers of psoriasis (p)  
compared to contact dermatitis (e),"eczema in psoriatico"(ep) and healthy skin (c). 
 
Figure 19. CD26 in “eczema in psoriatico” (ep), contact dermatitis (e), 
psoriasis (p) and in healthy skin (c). 
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5.1.4 Toll-like Receptor 4 (TLR4) 
TLR4 staining shows positivity in stratum basale of all stained samples including healthy 
skin controls. Psoriasis turned out to have a weaker staining of basal keratinocytes than “ec-
zema in psoriatico” (p≤0.01), allergic contact dermatitis (p≤0.1) and health controls.  
Evaluation of suprabasal layers of epidermis did not show and significant differences be-
tween “eczema in psoriatico”, contact dermatitis and psoriasis. Health controls turned out 
to have a weaker TLR4 expression than all examined inflammatory diseases (p≤0.05).   
TLR4 expression in superficial layers of epidermis showed a slightly stronger reaction in 
psoriasis compared to allergic contact dermatitis (p≤0.1). There were no statistical differences 
between “eczema in psoriatico” and contact dermatitis. TLR4 staining in superficial layers in 
health controls was negative. All results are presented in Figure 20 and 21.   
 
Figure 20. TLR4 in “eczema in psoriatico” (ep), contact dermatitis (e), psoriasis (p) and in healthy controls (c) 
 accordingly in basal-, suprabasal- und superficial layers. 
 
Figure 21. TLR4 in “eczema in psoriatico” (e), contact dermatitis (e), psoriasis (p) and in healthy controls (c). 
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5.1.5 Proliferation marker Ki67 
The results of immunostaining with Ki67 are shown in Figure 22, 23 and 24. 
Proliferation rate was highest in psoriasis with a mean number of 144 Ki67 positive keratino-
cytes, moderate in “eczema in psoriatico” and in allergic contact dermatitis, (accordingly 99 
and 81 positive cells) and low in healthy skin samples with a mean value of 48 positive cells. 
The major number of proliferating cells was distributed in stratum basale or directly su-
prabasal with a mean value of 97, 59, 43, and 37 accordingly in psoriasis, “eczema in psori-
atico”, allergic contact dermatitis and healthy skin samples. Statistical analysis using the 
Man-Whitney U test showed highly significant differences between psoriasis and contact 
dermatitis (p≤0.01), significant alterations between psoriasis and “eczema in psoriatico” 
(p≤0.05) and tendency (p≤0.1) between “eczema in psoriatico” and allergic contact dermatitis 
referring to Ki67 positive keratinocytes in the whole epidermis. These differences were more 
visible in stratum basale and directly suprabasal with highest significance (p≤0.001) between 
psoriasis and contact dermatitis and significance (p≤0.05) between psoriasis and “eczema in 
psoriatico” and between “eczema in psoriatico” and contact dermatitis. There were no sta-
tistical differences in the mean number of proliferating cells between psoriasis, “eczema in 
psoriatico” and contact dermatitis in upper stratum spinosum, stratum granulosum. 
Evaluation of Ki67 in slides coming from patients without elevated IgE in serum showed 
some alterations as presented in Figure 23. Patients with “eczema in psoriatico” with IgE 
within normal range showed a higher number of Ki67 positive cells than corresponding pa-
tients with “eczema in psoriatico” and elevated IgE. Consequently, there were no statistical 
differences between psoriasis and “eczema in psoriatico” in the whole epidermis and in basal 
layers. Both, psoriasis and “eczema in psoriatico” turned out to have the highest number of 
Ki67 positive cells compared to lower number found in contact dermatitis (p≤0.05) and in 
healthy skin (p≤0.05).  
,  
Figure 22. Ki67 positive cells in „eczema in psoriatico“(ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
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Figure 23. Ki67 positive cells in patients with IgE within normal range with  
"eczema in psoriatico"(ep),contact dermatitis (e), psoriasis (p) and in healthy skin (c). 
 
Figure 24. Ki67 positive cells in „eczema in psoriatico“(ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
5.1.6 Langerhans cells (CD1a) 
Dendritic cells were distributed throughout the epidermis and throughout the dermis in 
the inflammatory infiltrate. In all evaluated tissue samples, CD1a staining was stronger in 
epidermis than in dermis. In both epidermis and dermis, the highest number of positive cells 
was found in allergic contact dermatitis, followed accordingly by “eczema in psoriatico”, 
psoriasis and healthy skin (Figure 25, 26 and 27).  
Semi-quantitative analysis showed a statistical increase in the number of positive cells in 
epidermis in group of allergic contact dermatitis and “eczema in psoriatico” when compared 
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with the group of psoriasis (p≤0.01) and healthy skin samples (p≤0.001) (Figure 25). Less sta-
tistical differences were observed in the dermis with the highest number of positive CD1a in 
allergic contact dermatitis and “eczema in psoriatico” compared to psoriasis (accordingly 
p≤0.05 and p≤ 0.1). 
The same evaluation performed in patients without elevated IgE in serum showed some 
changes, as presented in Figure 26. Also in those cases, contact dermatitis turned out to have 
the highest number of positive cells compared to patients with “eczema in psoriatico” 
(p≤0.05) and psoriasis (p≤0.01), both without elevated IgE in serum. Patients with “eczema 
in psoriatico” and IgE within normal range, have less CD1a positive cells compared to pa-
tients with “eczema in psoriatico” and elevated IgE and consequently, no statistical differ-
ences with psoriasis. 
 
Figure 25. CD1a in "eczema in psoriatico", contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
 
Figure 26. CD1a in patients with IgE within normal range with "eczema in psoriatico"(ep),  
contact dermatitis (e), psoriasis (p) and in healthy skin (c). 
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Figure 27. CD1a in „eczema in psoriatico“(ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
5.1.7 Major histocompatibility complex I (MHC I) 
The positive staining (membrane-
like pattern with pericellular delinea-
tion) was observed in basal- and su-
prabasal epidermis layers. All examined 
slides showed positive staining in stra-
tum basale and negative staining in su-
perficial layers. Significant differences 
were observed only in the suprabasal 
layer: contact dermatitis and “eczema in 
psoriatico” showed MHC I overexpres-
sion, compared to psoriasis (p≤0.001) 
and to samples of healthy skin (p≤0.001). 
There were no statistical significant dif-
ferences in the number of MHC I-positive cells in dermal infiltrate between psoriasis, contact 
dermatitis and “eczema in psoriatico”. All results are illustrated in Figure 28 and 29. 
 
Figure 28. MHC I in suprabasal layers in “eczema in psoriatico” 
(ep), contact dermatitis (e), psoriasis (p),  
 and in healthy skin (c). 
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Figure 29. MHC I in “eczema in psoriatico” (ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
5.1.8 Major histocompatibility complex II (MHC II) 
MHC II positive cells were observed in epidermis and in dermis of all examined inflam-
matory diseases (ep, e, p).  
MHC II staining shows an increased number of positive cells in epidermis with Langerhans 
cells and lymphocytes morphology in contact dermatitis and in “eczema in psoriatico,” com-
pared to psoriasis (accordingly p≤0.01 and p≤0.001) and healthy controls (p≤0.001) (see Fig-
ure 30 and 31). MHC class II molecules were rarely expressed by keratinocytes.  
An elevated number of MHC II positive cells in dermis was observed in all inflammatory 
diseases, compared to healthy controls (p≤0.001). There were no statistical differences in the 
number of MHC II-positive cells in dermal infiltrate between psoriasis, contact dermatitis 
and “eczema in psoriatico”.  
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Figure 30. MHC II in “eczema in psoriatico” (ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
 
Figure 31.  MHC II in “eczema in psoriatico” (ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
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5.1.9 T-cell subsets: CD4+ and CD8+ 
The number of CD4+ and CD8+ T cells in both epidermal and dermal compartments; as 
well CD4+/CD8+ ratios are presented accordingly in Table 8 and Figure 32. 
There was an increased number of both CD4+ and CD8+ T-cell subsets in epidermal com-
partment in allergic contact dermatitis and in “eczema in psoriatico,” in comparison with 
psoriasis (p≤0.001) and healthy skin (p≤0.001). Regarding CD4/CD8 ratio, “eczema in psori-
atico” showed, in contrary to allergic contact dermatitis and psoriasis, the dominance of ep-
idermal CD8+ T cells over epidermal CD4+ T cells. Dominance of CD8+ T cells over CD4+ 
T cells was also observed in epidermis of healthy skin samples. 
CD4/CD8 ratio in dermis was highest in contact dermatitis (1.92), moderate in “eczema in 
psoriatico” (1.62) and lower in psoriasis (1.31) and in healthy skin (1.32). Regarding the num-
ber of CD4+ T cells in dermis, there were no statistical differences between eczema, “eczema 
in psoriatico” and psoriasis. All three diseases (ep, e, p) showed an up-regulated number of 
CD4+ T cells in dermis, compared with healthy skin (p≤0.001). 
Surprisingly, in “eczema in psoriatico”, there was an highly increased number of dermal 
CD8+ T cells, compared not only with healthy skin (p≤0.001), but also with allergic contact 
dermatitis (p≤0.01) and psoriasis (p≤0.001). This phenomenon is illustrated in Figure 33. 
Evaluation of T-cell subsets in patients without elevated IgE did not show any significant 
differences regarding CD4+ T cells in epidermis and dermis, as well as epidermal CD8+ 
T  cells in all examined diseases. Patients with “eczema in psoriatico” without increased IgE 
in serum also showed an elevated number of dermal CD8+ T cells compared to contact der-
matitis and psoriasis. These differences were statistically less prominent and accounted in 
both cases: p≤0.05. 
Illness 
 
Contact 
dermatitis 
e 
n=13 
Psoriasis 
 
p 
n=12 
Eczema in 
psoriatico 
ep 
n=33 
Healthy 
skin 
c 
n=5 
CD4/CD8 ratio 
epidermis: 
1.68 1.31 0.92 0.75 
CD4/CD8 ratio dermis: 1.92 1.31 1.62 1.32 
Table 8. CD4/CD8 ratio in contact dermatitis (e), psoriasis (p),  
"eczema in psoriatico"(ep) and in healthy skin (c). 
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Figure 32. T-cell subsets in “eczema in psoriatico” (ep), contact dermatitis (e), 
 psoriasis (p) and in helathy skin (c). 
 
Figure 33. Overexpression of CD8+ T cells in dermis of "eczema in psoriatico". 
5.1.10 Interleukin 8 (IL-8) 
IL-8 was positively stained in neutrophils, accumulated in stratum corneum and subcor-
neal (Figure 34). At the same time, IL-8 showed a distinct, intercellular, desmosome-like pat-
tern in basal and suprabasal keratinocytes and in inflammatory infiltrate in dermis (Fig-
ure  35). In single cases, especially in “in the field of” of acriosyringium, there was intracel-
lular keratinocyte reactivity.  
Due to accumulation of IL 8-positive neutrophils in parakeratosis, IL-8 staining in stratum 
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corneum was highest in psoriasis, moderate in “eczema in psoriatico” and lowest in allergic 
contact dermatitis. Statistical evaluation was as followed p≤0.01 between psoriasis and con-
tact dermatitis and p≤0.05 between psoriasis and “eczema in psoriatico” and between “ec-
zema in psoriatico” and contact dermatitis (Figure 34). 
 
Figure 34. IL-8 positive neutrophils subcorneal und in stratum corneum in psoriasis. 
-  
Figure 35. a: Desmosome-like pattern in basal- and suprabasal layers in contact dermatitis (e);  
b: desmosome-like pattern in dermal infiltrate in contact dermatitis (e). 
 
Figure 36. IL-8 desmosome-like staining in contact dermatitis (e), psoriasis (p),  
"eczema in psoriatico" (ep) and in healthy skin (c). 
As presented in Figure 35 and 36, the IL-8 desmosome-like staining was most prominent 
in the basal layer of epidermis. We observed a statistical significant overexpression of IL-8 in 
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allergic contact dermatitis when compared with psoriasis (p≤0.01) and with “eczema in pso-
riatico” in both basal- and suprabasal- layers (accordingly p≤0.05 and p≤0.01). There were no 
statistical significant differences between contact dermatitis, psoriasis and “eczema in psori-
atico” in superficial part of epidermis. No statistical differences were seen in dermal infiltrate.  
5.1.11 Interleukin 17 (IL-17) 
IL-17 positive cells were found in the upper 
and lower dermis. Analysis of skin samples by 
immunochemistry with IL-17 demonstrated 
IL- 17 in cells with neutrophil-, dendritic cell-, 
and especially, mast cell morphology (Figure 37). 
Healthy skin controls showed statistically de-
creased numbers of IL-17 positive cells com-
pared with “eczema in psoriatico” in both up-
per- and lower dermis (p≤0.01). There were no 
statistical differences in the number of positive 
cells between psoriasis and “eczema in psori-
atico” (both increased number). Semi-quantitative analysis of positive cells in the lower der-
mis showed a high significant increase (p≤0.01) in psoriasis group when compared with con-
tact dermatitis and a tendency (p≤0.1) comparing “eczema in psoriatico” with contact der-
matitis (Figure 38). These differences were less apparent in upper dermis- a statistically sig-
nificant increase of IL-17 positive cells (p≤0.05) was observed only in case of psoriasis com-
pared with contact dermatitis. 
 
Figure 38. IL-17 in upper- and lower dermis of “eczema in psoriatico” (ep), contact dermatitis (e),  
psoriasis (p) and in healthy skin (c). 
5.1.12 Interleukin 23 (IL-23) 
IL-23 positive cells were found mostly in papillary dermis (intravasal) and in Munro mi-
croabscesses. Most of the IL-23 positive cells had neutrophils' morphology (Figure 39).  
 
 Figure 37. IL-17 positive cells with morphology of mast 
cells. 
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There was an increased number of IL-23 positive cells in psoriasis and in “eczema in pso-
riatico,” compared to allergic contact dermatitis (accordingly p≤0.01 and p≤0.5). No statistical 
differences in the number of Il-23 positive cells were observed between psoriasis and “ec-
zema in psoriatico”. The results are presented in Figure 40. IL-23 positive cells were not ob-
served in healthy skin. 
5.1.13 Interleukin 31 (IL-31) 
IL-31 positive cells were distributed mainly throughout the upper dermis. IL-31 positive 
cells mostly had morphology of dendritic- and mast cells (Figure 41). Semi-quantitative anal-
ysis showed a statistical increase in the number of positive cells in group of “eczema in pso-
riatico“ and contact dermatitis when compared with the group of psoriasis (accordingly 
p≤0.05 and p≤0.1) and healthy skin (p≤ 0.001) (Figure 42). 
The same evaluation performed on slides coming from patients without elevated IgE levels 
 
Figure 41. IL-31 positive cells in dermis of  
"eczema in psoriatico". 
Figure 42. IL-31 positive cells in “eczema in psoriatico” 
(ep), contact dermatitis (e), psoriasis (p)  
and healthy skin (c). 
 
Figure 39. IL-23 positive cells  
with neutrophils morphology. 
Figure 40. IL-23 positive cells in “eczema in psoriatico” 
(ep), contact dermatitiis (e) psoriasis (p)  
and in healthy skin (c). 
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in serum did not show any statistical differences in the number of IL-31 positive cells be-
tween “eczema in psoriatico”, contact dermatitis and psoriasis.  
5.2 Discussion immunohistology 
5.2.1 Filaggrin 
Filament aggregating protein (filaggrin) is the main component of keratohyalin granules lo-
cated in stratum granulosum. Filaggrin shows a strong reactivity in healthy skin, encom-
passing 3-4 layers of stratum granulosum. A reduced filaggrin expression can be a result of 
alterations in epidermal differentiation or of filaggrin-loss-of-function mutations. Filaggrin 
carrier mutations status affects 8 to 10% of adults from the whole population [57,58] and up 
to 30-50% of patients with atopic dermatitis, particularly with severe course [59]. Its defi-
ciency leads to impaired skin barrier with an elevated transepidermal antigen penetration 
and an elevated water loss [60]. It is known that disruption of the skin barrier can lead to 
skin dryness [61] and to the development of ichthyosis vulgaris [62], atopic dermatits [57] or 
contact dermatitis of allergic or irritant type [63]. It was observed [64,65] that patients with 
filaggrin-loss-of-function mutations and no history of atopic dermatitis have more often dor-
sal hyperkeratosis, palmar hyperlinearity and intermittent skin fissures, especially during 
the winter. Dorsal skin changes (and sparse involvement of palms) in the “filaggrin hand 
eczema” was due to higher environmental exposure in that localisation. 
A reduced filaggrin expression in psoriasis has been already described, [36] and was dis-
cussed to reflect an altered epidermal differentiation (loss of stratum granulosum) and not 
genetic background with loss-of-function variants of the filaggrin gene. Filaggrin deficiency 
in psoriasis was also confirmed by Kim et al. [66]. It was suggested, that its origin is acquired 
and connected with TNF-α modulation. Treatment with anti-TNFα was found increased ex-
pression of filaggrin and loricrin in psoriatic lesions [67]. Profilaggrin and filaggrin reactivity 
in keratinocytes was found to be down-regulated by IL-22 [68]. Restoration of filaggrin pos-
itive cells was also observed under the therapy with calcipotriol [69]. 
Our study, “eczema in psoriatico” showed reduced filaggrin expression compared not only 
to contact dermatitis (p<0.001), but also to psoriasis (p<0.05). These results reflect alterations 
in epidermal differentiation with consecutive loss or thinning of stratum granulosum. Simi-
lar changes, but less prominent ones were observed in case of psoriasis. It can be speculated, 
that other factors such as type IV-sensitisation, atopy and irritants influence additional fil-
aggrin production and its distribution in “eczema in psoriatico”. 
On the other hand, examined slides with contact dermatitis had mostly “normal” and “linear” 
(=slightly reduced) filaggrin patterns, which could be explained by our inclusion criteria. 
Irritant palmoplantar eczema, as well as isolated atopic hand- and foot dermatitis cases were 
excluded from this study. Furthermore, the examined patients in particular, had a 
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palmoplantar manifestation - not as in case “filaggrin hand eczema” the involvement of dor-
sal sides of hands.  
5.2.2 Cytokeratines 16 and 17 (CK16, CK17) 
Cytokeratines are the basic structural components of keratinocytes. Basal keratinocytes 
normally express CK5 and CK14 and suprabasal keratinocytes: CK1 and CK10 [70,71]. 
CK16 reactivity is observed in the hyperproliferating epidermis of psoriasis, but not in 
healthy skin [70]. CK17 is not detected in normal human epidermis; and it is restricted to 
moyepithelial cells of the sweat glands and the deep outer root sheath [72]. Expression of 
CK17 in psoriatic epidermis is similar to that of CK16. Correspondingly, both CK16 and 
CK17 are postulated as sensitive markers of keratinocyte hyperproliferation in psoriasis, [70] 
and are useful in the evaluation of anti-psoriatic therapies. Reactivity of CK16 and CK17 in 
epidermal psoriasis was found to be reduced after the local treatment with anthralin and 
vitamin D3-analogue [72]. Changes in distribution of CK16 in psoriasis with normalisation 
in basal- and suprabasal layers were observed under the therapy with cyclosporin [71]. Dim-
inution of CK17 expression was observed also under the treatment with adalimumab [67]. 
Acitretin decreased, whereas hydrocortisone increased CK17 reactivity in a HaCaT keratino-
cyte model [73]. 
There are only a few studies examining the expression of CK16 and/or CK17 in contact der-
matitis. Willis et al. demonstrated high level expression of CK16 and only moderate expres-
sion of CK17 during the course of irritant contact dermatitis induced by sodium lauryl sulfate 
[74]. Le et al. observed marked increased epidermal reactivity of CK16 in both allergic and 
irritant contact dermatitis [75] and in other studies in 5 of 11 patients with chronic irritant 
contact dermatitis [76]. 
CK16- and CK17- expression turned out to be positive in psoriatic epidermis and negative in 
samples of healthy skin, as described by other authors [70,72]. In psoriasis, both stainings 
were positive in superficial- and suprabasal layers (whole stratum suprabasale in case of 
CK16 and upper suprabsasal layers in case of CK17). Similarly to other studies [74-76], CK16 
reactivity in contact dermatitis was also elevated, with positivity of suprabasal- and superfi-
cial layers. In comparison, CK17 showed only a slight increased expression in palmoplantar 
contact dermatitis compared with healthy skin and decreased expression compared with 
psoriasis (p< 0.05). This is why CK17, but not CK16 appears to be useful in differentiation of 
epidermal hyperproliferation between palmoplantar psoriasis and allergic contact dermati-
tis.  
Reactivity of CK16 and CK17 in “eczema in psoriatico” was increased and corresponded to 
that found in psoriasis. These results showed that “eczema in psoriatico” had the same alter-
ations in epidermal hyperproliferation as psoriasis. 
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5.2.3  Dipeptidyl peptidase IV (CD26) 
CD26 (Dipeptidyl peptidase IV = DP IV) is a membran glycoprotein with proteolytic 
properties. Inhibition of ectopeptidases like CD26 was found to influence different biological 
processes such as growth, apoptosis, differentiation and angiogenesis [77-79]. Inhibition of 
CD26 affects growth and functions of peripheral T lymphocytes [80]. In human skin, CD26 
is expressed on keratinocytes [81], sebocytes [82] and fibroblasts [83,84]. It was proved, that 
inhibitors of DP IV suppress keratinocyte proliferation in vitro [81] and may restore keratino-
cyte differentiation in vivo [85]. 
CD26 is known to be up-regulated in various inflammatory diseases like psoriasis and spon-
giotic diseases [86].  
Van Lingen et al. [87] demonstrated an epidermal overexpression of CD26 in psoriatic 
plaques, compared to uninvolved psoriatic skin and the healthy volunteers skin. Savoia et 
al. [88] observed normalised (reduced) reactivity of CD26 in psoriasis after treatment with 
calcipotriol. Psoriasis patients were found to have decreased CD26 expression of peripheral 
blood CD8+ T-cell subsets [89,90]. It was speculated, that this reduction may represent redis-
tribution of activated T cells into the dermal compartment [90].   
Increased CD26 reactivity in epidermis (with punctum maximum in stratum basale) was also 
observed in patients with atopic dermatitis and allergic contact dermatitis [91]. Similar re-
sults were demonstrated in both rat models of contact hypersensitivity [91].  
Our findings regarding psoriasis and contact dermatitis showed, in accordance to previous 
studies, an enhanced expression of epidermal CD26 staining in both diseases. To our 
knowledge, there are no studies comparing the reactivity of CD26 between psoriasis and 
chronic contact dermatitis. In our evaluation, psoriasis turned out to have stronger reactivity 
than contact dermatitis, especially in superficial layers (p≤0.1). “Eczema in psoriatico” 
showed a similar pattern to contact dermatitis. We demonstrated the statistical differences 
in CD26 staining between psoriasis and “eczema in psoriatico”, with stronger expression in 
the case of psoriasis in suprabasal- und superficial layers (accordingly p≤0.05 and p≤0.01). 
5.2.4 Toll-like Receptor 4 (TLR4) 
Toll like receptors (TLRs) are a family of cellular surface protein receptors, which recog-
nise pathogen-associated molecular patterns. TLRs are part of an innate system and initiate 
antimicrobial responses in various cells [92]. There are at least 10 functional TLRs, which 
have been identified in humans. TLR4 acts as a receptor of lipopolysaccharide (LPS) of gram-
negative bacteria inducing production of different cytokines and chemokines. 
It was proven, that human keratinocytes express TLR2 and TLR4 and play an important role 
as component of innate immunity [93].  
As microbial pathogens are known to aggravate psoriasis, TLRs were suggested to play a 
role in patomechanism of psoriasis. Resistance of psoriatic plaques to superinfection by 
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Staphylococcus aureus was also explained through increased levels of antimicrobial peptides 
found in psoriatic scales [94]. Expression of TLR and its role in psoriasis was investigated by 
different authors. Baker et al. observed an increased reactivity of TLR1, TLR2 and reduced 
reactivity of TLR5 compared psoriasis with normal skin[95]. TLR4 was found to be expressed 
by epidermal and dermal DCs and mid-epidermal KCs [96]. Due to an increased reactivity  
of TLR4 in psoriasis guttata, compared with psoriasis of plaque type, TLR4 was shown to 
play a role its pathogenesis [97]. TLR 4 was found to be a potent agonist of 
monomethylfumarate [98].  
TLR2 and TLR4 were proven to play a pivotal role in experimental model of allergic contact 
dermatitis [99]. Two different mechanisms were suggested. In IL-12-independent one, mice 
lacking both TLR2 and TLR4 failed to develop contact hypersensitivity. In IL-12-dependent 
one, failing response to IL-12 and the absence of single TLR2 or TLR4 prevents the develop-
ment of contact dermatitis. TLR4 is also known to play a crucial role in the development of 
contact allergy to nickel [100]. Schmidt et al have identified, that beside a hapten-specific 
T cell response, nickel can directly activate innate immune system via TLR4.  
In our observation, TLR4 showed an accentuation of stratum basale in healthy skin, allergic 
contact dermatitis and in “eczema in psoriatico”. Psoriasis turned out to have a weaker stain-
ing in basal layers than all other inflammatory diseases (p≤0.05) and also than healthy skin. 
On the other hand TLR4 staining in psoriasis showed reactivity in whole epidermis with 
tendency to up-regulation in superficial layers, when compared to ACD (p≤0.1). The TLR4 
pattern in “eczema in psoriatico” was similar to that - found in allergic contact dermatitis. 
5.2.5 Proliferation marker Ki67 
Ki67 is a proliferation marker, detecting a human nuclear antigen presented in prolifer-
ating cells [101]. Normal skin renewal is assisted by stem-like cells, of which only a small 
percentage can be triggered to proliferate [102]. Hyperproliferation of epidermal keratino-
cytes is one of the main characteristic features of psoriatic plaque. Expression of Ki67 was 
found to correlate with the psoriasis severity and was reduced under successful treatment, 
with for example, retinoids, methotrexate or cyclosporine [103-106]. 
There are only a few studies [107,108] examining the proliferation rate in contact dermatitis 
and to our knowledge, only single comparisons between psoriasis and eczema.  
Our study showed, that Ki67-positive cells were more abundant in psoriasis than in contact 
dermatitis and healthy skin (in the whole epidermis, respectively p≤0.01 and p≤0.001). “Ec-
zema in psoriatico” turned out to have moderately increased number of proliferating cells, 
lower than psoriasis (p≤0.05) and slightly higher than contact dermatitis (p≤0.1 in the whole 
epidermis and p≤0.05 in the basal layer).  
Interestingly the same evaluation in patients without elevated IgE in serum revealed en-
hanced number of Ki67 positive cells compared to patients with increased IgE. Consequently, 
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patients with “eczema in psoriatico”, who have a normal range of IgE showed the same pro-
liferation activity as patients with psoriasis. 
It can be speculated, that cellular turnover taking place in “eczema in psoriatico” can be de-
creased (in comparison to psoriasis) due to contemporary processes, characteristic for con-
tact sensitisation and atopy. 
5.2.6 Langerhans cells (CD1a) 
Cutaneous dendritic cells (DCs) can be divided in epidermal DCs (Langerhans cells, LCs) 
and dermal DCs (myeloid DCs and plasmacytoid DCs).  
Langerhans cells are antigen-presenting cells, representing 2-5% of the epidermal cell popu-
lation [109]. These play a crucial role in the development of allergic contact dermatitis. LCs 
are located fundamentally in suprabasal cell layers, where are bond to keratinocytes by E-
cadherins [110]. After antigen uptake, activated Langerhans cells move into dermis, enter 
lymphatic vessels, travel to the lymph nodes and present the antigen via MHC molecules to 
T lymphocytes. The role of LCs in psoriasis is not completely assessed. It was shown, that 
TLR-2 induced LCs can prime Th17 cells via IL-23, IL-1 β and TGF-β [111]. However, there 
are conflicting results regarding the number or density of LC in psoriasis. It is probably con-
nected with different LC numbers in the different stages or localisations [112]. Komine et al. 
[112] demonstrated that the number of LC was highest in the perilesional skin compared to 
lesional- and nonlesional psoriatic skin. Knowing that psoriatic plaque develops eccentri-
cally, it was suggested that LCs play an important role in the early plaque formation. De-
creased densities of LCs in psoriatic lesions were also found by Gordon KB et al. [113]. Res-
toration of epidermal DCs was observed by under the treatment with reinoids [114], psoralen 
plus ultraviolet (UV) A [115] , UVB [116] or ciclosporin [117] or adalimumab [113].  
Cumberbatch M et al. [118] proved an impaired Langerhans cell migration in psoriasis com-
pared to healthy skin of volunteers. These findings were confirmed also by Soyland et al 
[119]. It was observed that the count of CD1a positive cells in epidermis was reduced in le-
sional psoriatic skin compared to non-lesional psoriatic skin (in dermis, there were no sig-
nificant differences). Sun exposure leads to further reduction in LC number in epidermis, 
especially in non lesional skin. Only a slight reduction of LC numbers in lesional psoriatic 
epidermis suggested, according to authors, an impaired migratory function [119]. 
Dermal dendritic cells (dDCs) are also found to be of great importance in the pathogenesis 
of many inflammatory diseases. Several studies examined dDCs in the pathogenesis of pso-
riasis. 
Myeloid DCs expressing CD11c were found to be increased in number 30-fold compared 
psoriasis to healthy skin [120]. Myeloid DCs are important in the psoriasis' pathogenesis 
through its stimulation of Th1/Th17 T lymphocytes and production of numerous cytokines 
and chemokines, such as TNF-α or INF-α. It was observed, that lesional psoriatic skin, but 
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not skin from healthy donors contained DCs expressing IL23p19, which are known to pro-
mote the development and activation of Th17 cells [121].  
Antipsoriatic therapies such as PUVA or TNFα inhibitors were found to reduce the number 
of dermal dendritic cells [122]. Clinical improvement was observed under therapy with hu-
manised antibody anti-CD11a efalizumab, which led to reduction of myeloid DCs (medicine 
withdrawn from the market because of risk of progressive multifocal leukoencephalopa-
thy)  [123]. 
Plasmacytoid DCs expressing CD123 produce INF-α during viral infections, which stimu-
lates and regulates T lymphocytes and myeloid DCs [122]. INF-α produced by plasmocytoid 
DCs was found to play a role in the pathophysiology of psoriasis.  
Dendritic cells play an important role in atopic dermatitis and their number correlates with 
the disease activity [124,125].  
CD1a, an antibody directed against MHC molecules [126,127], is specific for LCs, but it can 
also be expressed on dermal dendritic cells [128].  
In our study, we performed only CD1a immunostaining. Our results confirm that epidermal 
LCs are highly increased in allergic contact dermatitis compared to healthy skin. The number 
of epidermal LCs in psoriasis turned out to be slightly higher than in healthy controls and 
statistically lower (p≤0.01) than in case of allergic contact dermatitis. The low number of ep-
idermal CD1a positive cells in psoriasis may depend on the localisation (in our case lesional 
skin samples) and on already described impaired migratory functions of LCs in psoriasis. 
“Eczema in psoriatico” showed more similarities with allergic contact dermatitis than with 
psoriasis. The count of epidermal LCs cells was lower than in allergic contact dermatitis 
(p≤0.05) and at the same time higher than in psoriasis (p≤0.01) and in healthy skin (p≤0.001). 
In the dermal compartment, the differences were less significant. 
The same evaluation performed in patients without elevated IgE in serum, revealed “psori-
asiform” pattern of “eczema in psoriatico”. There were no statistical differences between “ec-
zema in psoriatico” and psoriasis in the number of CD1a positive cells. Furthermore, chronic 
dermatitis turned out to have an elevated count of Langerhans cells, statistically higher than 
that of psoriasis (p≤0.05) and “eczema in psoriatico” (p≤0.01) without atopy. 
It can be speculated, that further characterisation of infiltrating DCs with other markers 
could enable a better understanding of the pathomechanism of “eczema in psoriatico”. Co-
existing atopy (elevated IgE levels) turns out to influence the number of CD1a positive cells 
in “eczema in psoriatico”. 
5.2.7 Major histocompatibility complex I (MHC I) 
MHC class I molecules are expressed at the surface of all nucleated cells and take part in 
presentation of endogenous peptide antigens to CD8+ cytotoxic T cells [31]. Expression of 
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MHC molecules is increased by cytokines production during both innate and adaptive im-
mune responses.  
The staining pattern of MHC I in psoriasis and in contact dermatitis has rarely been exam-
ined. Carlén et al. [129] observed variable expression levels of HLA-C (MHC class I heavy 
chain receptor) in epidermis between psoriasis and eczema. In psoriasis samples, there was 
a strong immunoreactivity of HLA-C in the basal cell layer and weak in suprabasal layers, 
whereas in contact dermatitis, a strong immunoreactivity in suprabasal layers was shown.  
Our findings are partially in accordance with the results of Carlén et al. [129]. We did not 
observe any statistical differences in MHC I reactivity between contact dermatitis, psoriasis, 
“eczema in psoriatico” and healthy skin in basal layers. The evaluation of MHC I staining in 
suprabasal layer appeared to be useful in differentiation of palmoplantar psoriasis from 
palmoplantar allergic contact dermatitis (highest significance in MHC I up-regulation in con-
tact dermatitis compared to psoriasis). “Eczema in psoriatico” showed a similar pattern to 
contact dermatitis with strong reactivity within basal- and suprabasal epidermis layers 
(p≤0.001 in suprabasal layers comparing “eczema in psoriatico” with psoriasis).  
Enhanced expression of MHC I molecules in allergic contact dermatitis and “eczema in pso-
riatico” correlate with elevated number of Langerhans cells and CD8+ T cells in epidermis in 
both diseases. In case of psoriasis, weaker reactivity of MHC I corresponded to lower number 
of Langerhans cells and of epidermal CD8+ T cells, in comparison to allergic contact derma-
titis and “eczema in psoriatico”. 
5.2.8 Major histocompatibility complex II (MHC II) 
MHC class II molecules are expressed on the antigen-presenting cells and present exog-
enous antigenic peptides to CD4+ T helper cells [31]. 
MHC class II molecules are detected on APC, B lymphocytes, activated T lymphocytes, Lang-
erhans cells, macrophages and endothelial cells [130]. In some conditions like MHC class 
molecules can be expressed by keratinocytes [130].  
Increased reactivity of MHC II in epidermis of allergic contact dermatitis and “eczema in 
psoriatico” correlated with elevated number of epidermal CD4+ cells, as well as Langerhans 
cells in both these diseases. In comparison to allergic contact dermatitis and “eczema in pso-
riatico”, psoriasis turned out to have less CD4+ epidermal T cells and Langerhans cells and 
an accordingly lower number of MHC II-positive T cells.  
5.2.9 T-cell subsets: CD4+ and CD8+ 
T lymphocytes play a crucial role in pathogenesis of psoriasis and contact dermatitis. In 
both disorders, they are polarised as type 1 (CD4+ and CD8+) and as Th17. Successful thera-
pies have been found to reduce their number [119]. 
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T lymphocytes can be divided in CD4+ (helper T lymphocytes) and CD8+ (cytotoxic T lym-
phocytes). In most tissues, the ratio of CD4+CD8- to CD8+CD4- cells is about 2: 1.  
In cell-mediated immunity, CD4+ T cells activate macrophages to destroy cells infected with 
intercellular microbes, and CD8+ T cells kill virus-infected cells. In humoral immunity, CD4+ 
T cells stimulate growth and differentiation of B cells [131]. 
Skin- associated lymphocytes are mostly located in dermis, especially perivascular and are 
represented by both CD4+ and CD8+ T lymphocytes. 2% of skin- associated lymphocytes 
reside in epidermis and belong mostly to CD8+ T cells. The expression of activation markers 
was observed in up to one-third of T cells [132]. It was found, that activated T lymphocytes 
in psoriatic skin secret cytokines such INF-γ and TNF-α [133]. 
Both allergic contact dermatitis and “eczema in psoriatico” showed an increased number of 
epidermal CD4+ and CD8+ T cells compared with psoriasis, which can be explained through 
lymphocytic exocytosis in epidermis.  
Our results confirmed that in psoriatic dermis, CD4+ T cells outnumber CD8+ T cells (the 
same in the case of allergic contact dermatitis and “eczema in psoriatico”). In contrary to 
other authors [134,135], we did not detect the CD8+ predominance in psoriatic epidermis (in 
our case CD4/CD8 ratio was 1.3:1). Predominance of epidermal CD8+ T cells was observed 
only in the case of “eczema in psoriatico” (CD4/CD8 ratio 0.92: 1) and in healthy skin 
(CD4/CD8 ratio 0.75: 1). 
Interestingly, “eczema in psoriatico” also had the highest count of dermal CD8+ T cells com-
pared with allergic contact dermatitis (p≤0.01) and psoriasis (p≤0.001).  
In other studies, epidermal CD8+ T cells were suggested to be a key player in the pathogen-
esis of psoriasis [135]. Deguchi et al. [136] examined proliferate activity of CD8+ T cells by 
double immunohistochemical staining (CD8/Ki67). Interestingly, CD8+ T cells with prolifer-
ating activity were located within the dermis and were not found in the epidermis. It was 
shown, that the number of CD8+/Ki67+ T cells in dermis in spongiotic dermatitis was signif-
icantly higher than in psoriasis. Most of the CD8+ T cells with proliferating activity were 
distributed in the lymphoid infiltrate in lesional dermis. It was speculated, that dermal den-
dritic cells could stimulate neighboring CD8+ T cells directly or via CD4+ T cells. In our study, 
we did not perform the double immunostaining with CD8 and Ki67. The accumulation of 
CD8+ T cells in the lymphoid infiltrate could suggest their proliferating activity. As already 
reported [136], in our observation contact dermatitis also turned out to have more dermal 
CD8+ positive cells than psoriasis. Surprisingly, the count of dermal CD8+ T cells in “eczema 
in psoriatico” outnumbered not only psoriasis, but also contact dermatitis.  
These results did not differ much from those obtained from the group of patients without 
elevated IgE in serum. Dermal CD8+ T cells in “eczema in psoriatico” with IgE within normal 
range were also elevated in comparison with contact dermatitis and psoriasis, but statisti-
cally less prominent (in both cases p≤0.05). 
Immunohistology 
Discussion immunohistology 
5.2 
 
61  
Further examination of cytotoxic T lymphocytes is required to understand the pathomecha-
nism of “eczema in psoriatico” better. 
5.2.10 Interleukin 8 (IL-8) 
Interleukin 8 is a secretory product of endothelial cells, fibroblasts and keratinocytes [137]. 
It is a marker of different inflammatory processes. Its reactivity was found to be increased in 
various inflammatory diseases like psoriasis, atopic- and contact- dermatitis [137,138]. IL-8 
is known for its neutrophil activating capacity, which includes chemotaxis, degranulation 
and generation of toxic oxygen radicals [137]. 
According to literature, distribution of IL-8 varies, and has different patterns, probably due 
to various staining procedures [139]. 
Our results regarding IL-8 staining in psoriasis were consistent with Ozawa et al. [139]. IL-8 
in psoriasis was detected in basal- and spinous keratinocytes as a desmosome-like pattern 
and in neutrophils accumulated sub- und intracorneal. Weak desmosome-like staining in 
basal keratinocytes was also seen in healthy controls. Surprisingly, the strongest intercellular 
staining in basal- and suprabasal keratinocytes was observed in allergic contact dermatitis. 
As expected, contact dermatitis had a weaker expression if IL-8 in stratum corneum in com-
parison to psoriasis, due to lower number of accumulated neutrophils. “Eczema in psoriatico” 
showed distinct characteristics of IL-8 staining with moderate desmosome-like patterns (less 
than in allergic contact dermatitis and more than in psoriasis) and moderate number of neu-
trophils both sub- und intracorneal (less than in psoriasis and more than allergic contact der-
matitis). In our observation, IL-8 did not show positive staining of any keratinocytes in upper 
epidermis (consistent with results of Ozawa et al). 
Desmosome-like staining of IL-8 is a finding of uncertain significance. The distribution of 
IL- 8 in epidermis was suggested to play a role in chemotaxis of neutrophils [139]. The en-
hanced reactivity of IL-8 staining in basal layers especially of contact dermatitis should be 
cleared and remains to be studied. 
5.2.11 Interleukin 17 (IL-17) 
Il-17 belongs to cell-derived proinflammatory cytokines. Recent research has demon-
strated that IL-17 is not only expressed by activated memory T-cells (Th17), but also by dif-
ferent cells of the innate immune system, like mast cells, neutrophils, dendritic cells, 
γδ-  T cells, macrophages and natural killer cells [140]. Lin AM. et al. have shown that mast 
cells are the majority of IL-17-containing cells in psoriatic skin [141], which also correlate 
with our observations. In our evaluation, secondly common IL-17 positive cells were neutro-
phils found both, in papillary dermis and in epidermal microabscesses- which reflect results 
of other studies [141]. 
IL-17 cytokine family consists of six members: IL-17A (our antibody, known also as IL-17 or 
CTLA-8) and IL-17B, IL-17C, IL-17D, IL-17E, IL-17F [142]. IL-17A is known to be a potent 
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inducer of IL-6 and IL-8 production by keratinocytes, fibroblasts and endothelial cells. These 
chemokines are involved in recruiting dendritic cells, Th17 cells and neutrophils. IL-17 drives 
the reactivity of ICAM-1 on keratinocytes. An increase of IL-17 was described in psoriasis 
[143-145], acute atopic dermatitis [146] and allergic contact dermatitis [143]. mRNA expres-
sion of IL-17A and IL-17F was found to be enhanced in lesional psoriatic skin, compared 
with nonlesional psoriatic skin [121,147-149]. It was suggested that IL-17 mRNA correlate 
with disease activity and therapy with cyclosporine leads to normalisation of its level [148]. 
Recent preliminary clinical studies show that IL-17 inhibitors are effective in psoriasis treat-
ment [150]. IL-17 positive T cells were also found at the site of spongiosis in allergic contact 
dermatitis and were shown to amplify allergic reactions [151].  
Our findings show an increased number of IL-17 positive cells (especially with morphology 
of mast cells and neutrophils) in the case of psoriasis and “eczema in psoriatico” compared 
to healthy skin (p≤0.01) in the whole dermis. IL-17 positive cells infiltrating dermis in allergic 
contact dermatitis were slightly increased compared to healthy controls, but lower than in 
the case of psoriasis (p≤0.1) and “eczema in psoriatico” (p≤0.01).  
5.2.12 Interleukin 23 (IL-23) 
IL-23 is secreted by activated dendritic cells, phagocytic cells and keratinocytes. IL-23 
promotes the development and activation of Th17 cells. IL-23 plays a crucial role in the pato-
mechanism of psoriasis. The neutralizing IL12/23p40 antibody was found to be effective in 
the treatment of psoriasis patient [152,153]. 
There are some studies describing the IL-23 cells in the lesional psoriatic skin. Wilson et al. 
observed an increased number of dendritic cells expressing IL-23p19 in lesional psoriatic 
skin [121]. Lilis J et al. [154] noted an increased number of IL-23 positive cells in the papillary 
dermis of plaque psoriasis, palmoplantar psoriasis and hyperkeratotic hand dermatitis com-
pared with nonlesional psoriasis skin (no statistical differences in these groups). 
In our observation, IL-23 positive cells have neutrophils´ morphology. As expected, the high-
est number of IL-23 positive cells was observed in psoriasis and lowest in contact dermatitis. 
“Eczema in psoriatico” showed similar patterns to psoriasis. 
5.2.13 Interleukin 31 (IL-31) 
IL-31 plays an important role in atopic dermatitis and was demonstrated to induce pru-
ritic skin changes resembling atopic dermatitis in IL-31 over-expressing transgenic mice [155]. 
IL-31 was found to be up-regulated in pruritic atopic dermatitis, compared to non-pruritic 
psoriasis, and to healthy skin [156]. 
In our study, we observed an increased number of IL-31 positive cells in “eczema in psori-
atico” compared to psoriasis (accordingly p≤0.5) and healthy skin (p≤0.001). Exclusion of 
patients with elevated IgE in serum led to other results, namely there were no statistical dif-
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ferences between “eczema in psoriatico”, contact dermatitis and psoriasis. It can be sug-
gested that level of IgE in serum correlates with the number of IL-31 positive cells in dermis 
of the examined inflammatory diseases.  
5.3 Summary 
Understanding of pathomechanism of “eczema in psoriatico” was the most relevant part 
of this thesis. At the beginning, we performed a detailed analysis of different immunological 
processes in palmoplantar psoriasis and palmoplantar allergic contact dermatitis in compar-
ison to healthy skin. In the next step, we evaluated the immunological patterns in “eczema 
in psoriatico” looking for similarities and differences in psoriasis and contact dermatitis. 
Our study enabled a better immunohistological differentiation between psoriasis and 
chronic allergic contact dermatitis in palmoplantar localisation.  
Our results clarified processes taking part in “eczema in psoriatico”. Precise evaluation 
of different immunostainings revealed similar alterations in epidermal differentiations in 
both psoriasis and “eczema in psoriatico” (CK17, Ki67). “Eczema in psoriatico” showed con-
temporarily overlapping features with psoriasis (IL-8, IL-17 and IL-23) and contact dermati-
tis (CD1a, MHC I, MHC II, epidermal T cell subsets). Surprisingly, we discovered an in-
creased number of dermal CD8+ T cells, in comparison not only with psoriasis, but also con-
tact dermatitis. Elevated IgE in serum turned out to negatively influence the number of Ki67- 
and positively the number of CD1a- and IL-31 positive cells. 
The most important results are summarised in the Figure 43.  
 
 
 
 
 
 
Figure 43. Results of immunohistological studies. 
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6. Conclusion 
Scaling erythematous plaques on palms and soles often cause diagnostic difficulties. Dif-
ferential diagnosis between psoriasis and chronic contact dermatitis in palmoplantar locali-
sation is, due to overlapping clinical and histological features, hardly possible by isolated 
involvement.  
However, proper diagnosis is important for successful therapy and discussion of occupa-
tions' triggering such conditions. Persistent palmoplantar skin changes have a big impact on 
life quality and may often result in long-term sickness, work-related absences and conse-
quently on long-term unemployment.  
In our observations, there is a large group of patients with erythrosquamous plaques on 
palms and soles that show clinical and histological features of psoriasis and contact derma-
titis combined with a high frequency of positive patch tests. This constellation is mostly 
called "eczema in psoriatico". This separate entity encloses a major part of patients with un-
clear clinical and histological picture. Therefore, the focus of this thesis was to investigate a 
clinical, histological and immunohistological features of these patients compared to typical 
palmoplantar psoriasis, typical allergic contact dermatitis and healthy skin. 
The first point of this work was to characterise the clinical manifestations in the different 
groups of patients. As most of the patients had an isolated palmoplantar involvement, final 
diagnosis was based on results of allergy tests and on histological and immunohistological 
proprieties of skin samples. In a small percentage, nail- and scalp involvement helped to 
favour the diagnosis of psoriasis and/or “eczema in psoriatico”. As already mentioned, patch 
test were positive in all patients with contact dermatitis and “eczema in psoriatico” (inclu-
sion criteria) with metals (nickel sulfate, potassium dichromate, cobalt), balsam of Peru, fra-
grance mixes and formaldehyde as the most common contact allergens. Surprisingly, in 
more than 50% patients (5/9) with palmoplantar psoriasis, there were weak, positive patch 
tests results, without clinical and histological features of contact sensitisation. Strong patch 
reactions (≥++) were observed only in group of contact dermatitis and “eczema in psoriatico” 
and in no patients with palmoplantar psoriasis. Estimation of IgE levels in serum revealed 
elevated values in 40% of patients with psoriasis, 76.2% of patients with “eczema in psori-
atico” and in only 18.2% of patients with contact dermatitis. Limitation of this test was due 
to the fact, that estimation of IgE in serum was not performed in all patients (in 11 of 13 with 
contact dermatitis, 5 of 12 with psoriasis and in 21 of 30 with “eczema in psoriatico”). Ele-
vated IgE in serum turned out to correlate with an increased number of CD1a and IL-31 in 
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immunohistology. 
Histologic evaluation of all slides with H&E staining was another important point of this 
study. “Eczema in psoriatico” turned out to have overlapping features with both psoriasis 
and contact dermatitis. The following features were shared with psoriasis: moderate to 
strong parakeratosis, regular acanthosis, loss or thinning (also partially) of granular layer, 
thinning of suprapapillary plates, oedema of papillary dermis and presence of Munro mi-
croabscesses. Further features of “eczema in psoriatico” were shared with contact dermatitis: 
neutrophils and plasma exudation in parakeratosis, lymphocytic exocytosis in epidermis, 
full-thickness spongiosis or formations of spongiotic vessels. 
The most challenging part of the investigative studies was the performance of numerous 
immunohistological stainings, their quantification and comparison between all examined 
groups: contact dermatitis, psoriasis, “eczema in psoriatico” and healthy skin samples. It was 
shown that “eczema in psoriatico” has similar alternations in epidermal proliferation to pso-
riasis (CK17, Ki67). Due to the loss of granular layer, reduction of filaggrin staining was more 
pronounced in “eczema in psoriatico” than in psoriasis and contact dermatitis. CK16 turned 
out to be unhelpful in the differentiation of epidermal hyperproliferation in contact derma-
titis, psoriasis and “eczema in psoriatico” (all samples showed similar positive reactions). 
Increased number of IL-8-, IL-17-, IL-23 positive cells was found in both psoriasis and in 
“eczema in psoriatico”. Overexpression of CD1a-, MHC I- and MHC II positive cells was 
shared by contact dermatitis and “eczema in psoriatico”. In the case of CD1a, the number of 
positive cells varied according to the presence of elevated IgE in serum. The evaluation of 
T cells subsets in epidermis revealed an elevated number of CD4+ and CD8+ T cells in both 
contact dermatitis and “eczema in psoriatico”, which corresponded to lymphocytic exocyto-
sis observed in H&E stains. Surprisingly, “eczema in psoriatico” showed an up-regulated 
number of CD8+ dermal T cells compared not only to psoriasis but also to contact dermatitis. 
The significance of this finding should be examined further. The density of IL-31 positive 
cells turned out to correlate with elevated IgE in serum und was highest in “eczema in pso-
riatico”.  
Our work provides a better understanding of not only the pathomechanism of “eczema 
in psoriatico”, but also of psoriasis and contact dermatitis in palmoplantar localisation.  
In the case of therapy resistant scaling erythema on palms and soles, we suggest detailed 
examination of the whole skin with its derivatives, performance of the patch tests, estimation 
of IgE in serum, as well as skin biopsies for further histological and immunohistological eval-
uation. Histologic pictures of “eczema in psoriatico” reveal psoriasiform dermatitis with 
lymphocytic exocytosis and spongiosis. Just with the help of single immunostainings such 
as CK17, CD1a and CD8, a major part of unclear cases can be classified accordingly. 
This research showed that the clinical picture of palmoplantar psoriasis can be influenced 
markedly by coexisting contact allergy. 
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Psoriasis and chronic eczema at the palmoplantar sites show multiple overlapping clini-
cal and histological features. The differentiation, especially by the lack of other skin changes 
is often hardly possible. In the last ten years in our department, we have observed a large 
group of patients with type IV-sensitisation, showing contemporarily clinical and histologi-
cal features of both psoriasis and contact dermatitis. This constellation is called, in particular 
by us, but also occasionally in literature "eczema in psoriatico". 
The purpose of the instant study was to compare clinical, histological and immunohisto-
logical characteristics of these patients with typical palmoplantar psoriasis and typical 
palmoplantar contact dermatitis.  
Two highly experienced dermatopathologists performed a blind evaluation of 142 sam-
ples referring to psoriasis, contact dermatitis or “eczema in psoriatico“. From this collective, 
a final selection of 63 specimens obtained from 59 patients arose, in which both experts made 
a consistent diagnosis: 33 with “eczema in psoriatico”, 13 with allergic contact dermatitis and 
12 with psoriasis. 5 samples of healthy skin in palmoplantar localisation were added addi-
tionally. Cases with chronic irritant non-allergic hand and foot manifestations, as well as 
those with isolated atopic hand dermatitis and psoriasis pustulosa palmoplantaris were ex-
cluded from this study. Hereby, we were able to generate a selective and well-defined col-
lective for further evaluation. 
Patients with positive patch tests results were assessed in parallel. The frequency of type 
IV sensitisation with the most common allergens was compared in relation to quality, as well 
as to the quantity of the reaction. Elevated IgE in serum was a common finding in the group 
with “eczema in psoriatico”. 
To assess routine histological sections, we chose 14 parameters that according to our ex-
perience and to the literature were considered helpful in the differentiation between psoria-
sis from contact dermatitis. In this connection, “eczema in psoriatico” showed overlapping 
histological features with both diseases. The routine histological staining turned out to be 
insufficient for the distinction of these diseases from one another. 
By immunochemistry, “eczema in psoriatico” presented similar alterations in epidermal 
hyperproliferation to psoriasis (CK17, Ki67). The loss of granular layer and consequently 
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reduction of filaggrin expression was more pronounced in “eczema in psoriatico” than in 
psoriasis and contact dermatitis. CK16 turned out to be of no use in the differentiation of 
epidermal hyperproliferation between “eczema in psoriatico“, contact dermatitis and psori-
asis. “Eczema in psoriatico“revealed similarities with psoriasis in regard to the expression of 
IL-8, IL-17 and IL-23. An increased number of CD1a- , MHC I- and MHC II positive cells was 
characteristic of contact dermatitis and “eczema in psoriatico”. In both of them, lymphocytic 
exocytosis into epidermis could be observed, showing an elevated number of CD4+ and 
CD8+ T cells. Surprisingly, “eczema in psoriatico” revealed a significantly higher number of 
dermal CD8+ T cells than contact dermatitis and psoriasis. Elevated levels of IgE in serum 
correlated positively with the number of epidermal CD1a- and dermal IL-31- positive cells. 
Altogether, due to some immunohistochemical constellations, „eczema in psoriatico“can 
be differentiated better from palmoplantar- contact dermatitis and psoriasis. The immuno-
histological analysis shows that in the case of specimens obtained from “eczema in psori-
atico”, a small set of immunological markers specific to both diseases are found contempo-
raneously. Our work, therefore, provides a better understanding of the pathomechanism of 
psoriasis and contact dermatitis in palmoplantar localisation. In our opinion, “eczema in 
psoriatico“is a distinct clinical entity, and, of particular importance, with regard to occupa-
tional diseases associated with different clinical diagnostic and therapeutic consequences. 
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Zusammenfassung 
Die Psoriasis und das chronische Kontaktekzem in palmo-plantarer Lokalisation zeigen 
überlappende klinische und histologische Merkmale. Häufig ist die Abgrenzung, besonders 
beim Fehlen typischer lokalisationsferner Hauterscheinungen schwierig. Wir haben wäh-
rend der letzten 10 Jahre im Patientengut unserer Klinik eine größere Gruppe von Patienten 
mit allergischer Typ IV-Kontaktsensibilisierung beobachtet, die sowohl klinische als auch 
histologische Eigenschaften einer Psoriasis und eines Kontaktekzems aufweisen. Diese 
Konstellation wird besonders von uns, aber auch gelegentlich in der Literatur als „Eczema 
in psoriatico“ genannt. Zielsetzung der vorliegenden Arbeit war es, klinische, histologische 
und immunohistologische Eigenschaften dieser Patienten mit palmo-plantarer Psoriasis und 
mit palmo-plantarem allergischem Kontaktekzem zu vergleichen. 
 
Zwei langjährig erfahrene Dermatopathologen führten zunächst eine Blindbegutachtung 
von 142 Gewebeproben durch, in denen Hinweise bzw. Diagnosen für eine Psoriasis, ein 
Ekzem oder ein „Eczema in psoriatico“ geäußert worden waren. Aus dieser Gesamtprobe 
ergab sich schließlich eine aus beiden Evaluationen übereinstimmende Auswahl von 63 Bi-
opsien von 59 Patienten, die sich von beiden Evaluierern einer Diagnose zuordnen ließ: 33 
mit „Eczema in psoriatico“, 13 mit allergischem Kontaktekzem und 12 mit Psoriasis palmo-
plantaris. 5 gesunde Kontrollen mit gleicher Lokalisation der Hautbiopsien wurden hinzu-
genommen. Solche Patienten mit klinisch rein chronisch irritativer, d.h. nicht allergischer 
Kontaktdermatitis, solche mit isoliertem atopischem Handekzem bei atopischer Diathese 
bzw. atopischer Dermatitis und solche mit Psoriasis pustulosa palmo-plantaris wurden aus-
geschlossen. Hierdurch konnte ein selektiertes und definiertes Kollektiv zur Evaluation her-
angezogen werden. 
 
Patienten mit positiven Reaktionen im Epikutantest wurden parallel evaluiert und die 
Frequenz der Typ-IV Sensibilisierung mit den häufigsten Allergenen verglichen in Hinsicht 
auf die Qualität wie auch auf die Quantität der Reaktion. In der Gruppe der Patienten mit 
„Eczema in psoriatico“ wurde eine erhöhte Frequenz von IgE-Werten beobachtet. 
 
Für die Beurteilung der routinehistologischen Parameter bzw. weiterführender Färbun-
gen wurden 14 Parameter ausgewählt, die für die Differenzierung einer Psoriasis gegenüber 
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einem Kontaktekzem hilfreich sein könnten bzw. in der Literatur beschrieben wurden. Hier-
bei zeigte sich, dass das „Eczema in psoriatico“ überlappende histologische Merkmale bei-
der Krankheiten aufweist und H&E Färbung nur ungenügend zur Differenzierung beiträgt. 
 
Bei der immunohistologischen Evaluierung zeigte das „Eczema in psoriatico“ ähnliche 
Veränderungen in der epidermaler Differenzierung wie die Psoriasis (CK17, Ki67). Das meist 
fehlende Stratum granulosum konnten wir im Falle des „Eczema in psoriatico“ im Sinne 
einer verminderten Reduktion der Filaggrin-Expression deutlicher als bei Psoriasis und Kon-
taktdermatitis finden. Ein Proliferationsmarker für Keratin CK16 stellte sich nicht als hilf-
reich in der Differenzierung epidermaler Veränderungen zwischen Kontaktdermatitis, Pso-
riasis und „Eczema in psoriatico“ heraus. Das „Eczema in psoriatico“ wies hingegen Ähn-
lichkeiten mit einer Psoriasis in Hinsicht auf die Expression und das Muster der Expression 
von IL8-, IL-17 und IL-23 auf. Eine erhöhte Zahl von CD1a-, MHC I- und MHC II-positiven 
Zellen war charakteristisch für die allergische Kontaktdermatitis und das „Eczema in psori-
atico“. In beiden klinischen bzw. histologischen Fällen wurde eine lymphozytäre Exozytose 
mit CD4+ und CD8+ Zellen nachgewiesen. Erstaunlicherweise fand sich jedoch beim 
„Eczema in psoriatico“ eine signifikant höhere Zahl von dermalen CD8+ Zellen als bei der 
Kontaktdermatitis oder bei der Psoriasis. Die erhöhten Serumwerte für das Gesamt-IgE kor-
relierten positiv mit der Zahl epidermaler CD1a- und dermaler IL-31- positiver Zellen. 
Zusammenfassend kann mit Hilfe einer kleinen umschriebenen immunohistochemi-
schen Konstellation das „Eczema in psoriatico“ allergischer Genese gegenüber der allergi-
schen Kontaktdermatitis sowie gegenüber der normalen Psoriasis in palmo-plantarer Loka-
lisation besser abgegrenzt werden. Die immunohistochemischen Parameter zeigten, dass 
beim “Eczema in psoriatico” typische immunologische Marker der Psoriasis und Kontakt-
dermatitis sich gleichzeitig im Bioptat  finden, aber mit wenigen anderen Merkmalen diffe-
renziert werden können. Die vorliegende Dissertation ermöglicht ein weiteres besseres Ver-
ständnis der Pathomechanismen von Psoriasis und allergischem Kontakekzem in palmo-
plantarer Lokalisation zu erkennen. Das „Eczema in psoriatico“ ist, unserer Meinung nach, 
eine klinische Entität, die darüber hinaus von besonderer gutachterlicher Bedeutung bei 
Berufsdermatosen ist, sowie auch eine andere therapeutische Konsequenz nach sich zieht. 
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